<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nat Genet</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nat. Genet.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Nature genetics</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1061-4036</issn>
        <issn pub-type="epub">1546-1718</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC3432702</article-id>
        <article-id pub-id-type="pmcid-ver">PMC3432702.1</article-id>
        <article-id pub-id-type="pmcaid">3432702</article-id>
        <article-id pub-id-type="pmcaiid">3432702</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS390374</article-id>
        <article-id pub-id-type="pmid">22842228</article-id>
        <article-id pub-id-type="doi">10.1038/ng.2359</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS390374</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA390374</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Exome sequencing identifies recurrent somatic <italic toggle="yes">RAC1</italic> mutations in melanoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Krauthammer</surname>
              <given-names initials="M">Michael</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kong</surname>
              <given-names initials="Y">Yong</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ha</surname>
              <given-names initials="BH">Byung Hak</given-names>
            </name>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Evans</surname>
              <given-names initials="P">Perry</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bacchiocchi</surname>
              <given-names initials="A">Antonella</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>McCusker</surname>
              <given-names initials="JP">James P</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cheng</surname>
              <given-names initials="E">Elaine</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Davis</surname>
              <given-names initials="MJ">Matthew J</given-names>
            </name>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Goh</surname>
              <given-names initials="G">Gerald</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Choi</surname>
              <given-names initials="M">Murim</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ariyan</surname>
              <given-names initials="S">Stephan</given-names>
            </name>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Narayan</surname>
              <given-names initials="D">Deepak</given-names>
            </name>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dutton-Regester</surname>
              <given-names initials="K">Ken</given-names>
            </name>
            <xref ref-type="aff" rid="A9">9</xref>
            <xref ref-type="aff" rid="A10">10</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Capatana</surname>
              <given-names initials="A">Ana</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Holman</surname>
              <given-names initials="EC">Edna C</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bosenberg</surname>
              <given-names initials="M">Marcus</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sznol</surname>
              <given-names initials="M">Mario</given-names>
            </name>
            <xref ref-type="aff" rid="A11">11</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kluger</surname>
              <given-names initials="HM">Harriet M</given-names>
            </name>
            <xref ref-type="aff" rid="A11">11</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Brash</surname>
              <given-names initials="DE">Douglas E</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="aff" rid="A12">12</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Stern</surname>
              <given-names initials="DF">David F</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Materin</surname>
              <given-names initials="MA">Miguel A</given-names>
            </name>
            <xref ref-type="aff" rid="A13">13</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lo</surname>
              <given-names initials="RS">Roger S</given-names>
            </name>
            <xref ref-type="aff" rid="A14">14</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mane</surname>
              <given-names initials="S">Shrikant</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="aff" rid="A15">15</xref>
            <xref ref-type="aff" rid="A16">16</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ma</surname>
              <given-names initials="S">Shuangge</given-names>
            </name>
            <xref ref-type="aff" rid="A17">17</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kidd</surname>
              <given-names initials="KK">Kenneth K</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hayward</surname>
              <given-names initials="NK">Nicholas K</given-names>
            </name>
            <xref ref-type="aff" rid="A10">10</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lifton</surname>
              <given-names initials="RP">Richard P</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schlessinger</surname>
              <given-names initials="J">Joseph</given-names>
            </name>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Boggon</surname>
              <given-names initials="TJ">Titus J</given-names>
            </name>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Halaban</surname>
              <given-names initials="R">Ruth</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A2"><label>2</label>Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A3"><label>3</label>W.M. Keck Foundation Biotechnology Resource Laboratory, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A4"><label>4</label>Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A5"><label>5</label>Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A6"><label>6</label>Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A7"><label>7</label>Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A8"><label>8</label>Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A9"><label>9</label>Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia</aff>
        <aff id="A10"><label>10</label>Department of Genetics and Computational Biology, Queensland Institute of Medical Research, Brisbane, Queensland, Australia</aff>
        <aff id="A11"><label>11</label>Comprehensive Cancer Center, Section of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A12"><label>12</label>Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A13"><label>13</label>Department of Ophthalmology, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A14"><label>14</label>Department of Medicine, Division of Dermatology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA</aff>
        <aff id="A15"><label>15</label>Center for Human Genetics and Genomics, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A16"><label>16</label>Program on Neurogenetics, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <aff id="A17"><label>17</label>School of Public Health, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
        <author-notes>
          <corresp id="FN1">Correspondence should be addressed to R.H. (<email>ruth.halaban@yale.edu</email>)</corresp>
        </author-notes>
        <pub-date pub-type="epub">
          <day>29</day>
          <month>7</month>
          <year>2012</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <month>9</month>
          <year>2012</year>
        </pub-date>
        <volume>44</volume>
        <issue>9</issue>
        <issue-id pub-id-type="pmc-issue-id">213583</issue-id>
        <fpage>1006</fpage>
        <lpage>1014</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>09</day>
              <month>07</month>
              <year>2012</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>03</month>
              <year>2013</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>03</month>
              <year>2013</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-04-17 14:25:22.797">
              <day>17</day>
              <month>04</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <license>
            <license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: 
<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms390374.pdf"/>
        <abstract>
          <p id="P1">We characterized the mutational landscape of melanoma, the form of skin cancer with the highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed melanomas had markedly more ultraviolet (UV)-like C&gt;T somatic mutations compared to sun-shielded acral, mucosal and uveal melanomas. Among the newly identified cancer genes was <italic toggle="yes">PPP6C</italic>, encoding a serine/threonine phosphatase, which harbored mutations that clustered in the active site in 12% of sun-exposed melanomas, exclusively in tumors with mutations in <italic toggle="yes">BRAF</italic> or <italic toggle="yes">NRAS</italic>. Notably, we identified a recurrent UV-signature, an activating mutation in <italic toggle="yes">RAC1</italic> in 9.2% of sun-exposed melanomas. This activating mutation, the third most frequent in our cohort of sun-exposed melanoma after those of <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic>, changes Pro29 to serine (RAC1<sup>P29S</sup>) in the highly conserved switch I domain. Crystal structures, and biochemical and functional studies of RAC1<sup>P29S</sup> showed that the alteration releases the conformational restraint conferred by the conserved proline, causes an increased binding of the protein to downstream effectors, and promotes melanocyte proliferation and migration. These findings raise the possibility that pharmacological inhibition of downstream effectors of RAC1 signaling could be of therapeutic benefit.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <p id="P2">Identification of mutations in cancer cells that drive malignant transformation has opened the door to patient-tailored targeted therapies that improve overall survival. For example, inhibitors of activating mutations in <italic toggle="yes">BRAF</italic>, which are present in ~50% of cutaneous melano-mas<sup><xref rid="R1" ref-type="bibr">1</xref></sup>, can have substantial therapeutic benefit<sup><xref rid="R2" ref-type="bibr">2</xref>–<xref rid="R4" ref-type="bibr">4</xref></sup>. Attempts to inhibit <italic toggle="yes">NRAS,</italic> which is mutated in 15–20% of all tumor types<sup><xref rid="R5" ref-type="bibr">5</xref></sup>, have been less successful. Exome or whole-genome sequencing has been used to identify new mutations in melanomas, but to date, studies using these methods have been limited to 25 or fewer tumors<sup><xref rid="R6" ref-type="bibr">6</xref>–<xref rid="R9" ref-type="bibr">9</xref></sup>. To reveal the scope of melanoma mutations more comprehensively, we performed exome sequencing of 147 primary or metastatic melanomas (<xref rid="SD1" ref-type="supplementary-material">Supplementary Tables 1 and 2</xref>). The results identified previously unreported genes and pathways that have a role in melanoma pathogenesis, including effectors for a new gain-of-function mutation that may be amenable to targeted therapy.</p>
      <sec sec-type="results" id="S1">
        <title>RESULTS</title>
        <sec id="S2">
          <title>Landscape of nonsynonymous somatic mutations</title>
          <p id="P3">The analysis of protein-altering somatic mutations in 147 melanomas, based on comparison to matched germline DNA (referred to here as matched samples), revealed a total of 23,888 missense and 1,596 nonsense mutations, 399 splice-site variants and 282 insertions/deletions (indels). Melanomas originating from hair-bearing skin, such as the trunk, arms, legs or head (referred to here as sun-exposed melano-mas) had markedly more somatic mutations than melanomas originating from hairless skin such as palms and soles (acral melanoma), as well as mucosal and uveal melanomas (collectively referred to as sun-shielded melanomas), with a median count of 171 mutations per sun-exposed tumor and 9 mutations per sun-shielded tumor (<italic toggle="yes">P</italic> = 1.6 × 10<sup>−5</sup>). Melanomas with mutations in either <italic toggle="yes">BRAF</italic> or <italic toggle="yes">RAS</italic> were mostly in the center of the mutation load distribution, with a median of 156.5 mutations (<xref rid="F1" ref-type="fig">Fig. 1a</xref>). Tumors with more than 500 somatic mutations were found in older patients (median age of 80.5 years compared to a median age of 65.0 years for the tumors with 500 or less mutations), with a high percentage of primary lesions in these patients on the head and neck (77%), which is a hallmark of chronic sun-damaged melanomas<sup><xref rid="R10" ref-type="bibr">10</xref></sup>. The number of mutations generally increased with patient age (<xref rid="F1" ref-type="fig">Fig. 1b</xref>, Pearson correlation coefficient of 0.4, <italic toggle="yes">P</italic> = 0.0015). The tumors with wild-type <italic toggle="yes">BRAF</italic> and <italic toggle="yes">RAS</italic> with low mutation counts were primarily from sun-shielded sites.</p>
          <p id="P4">The higher number of single-base mutations in sun-exposed melanomas was accounted for by mutations linked to UV-induced DNA damage, with an excess of C&gt;T mutations in the dipyrimidines, including CC&gt;TT, in both exonic and intronic sequences (<xref rid="F1" ref-type="fig">Fig. 1c</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 1a</xref>). There were 2.93-fold more C&gt;T transitions in dipyrimidine sequences in the nontemplate compared to the template strand of expressed genes. The corresponding ratio of these transitions in nonexpressed genes was 0.96. These findings are consistent with transcription-coupled repair of mutations in the template strand of expressed genes<sup><xref rid="R6" ref-type="bibr">6</xref></sup>. We did not observe a higher number of C&gt;T mutations in the dipyrimidine sequences in sun-shielded melanomas (<xref rid="F1" ref-type="fig">Fig. 1c</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 1a</xref>) or a significant difference in the C&gt;T ratio for the nontranscribed compared to the transcribed strands in either expressed or nonexpressed genes in these tumors (1.19 and 0.91, respectively).</p>
          <p id="P5">The extended sequence context had a large effect on mutation frequency in sun-exposed melanomas (<xref rid="F1" ref-type="fig">Fig. 1d</xref>). For example, whereas the overall mutation frequency for a cytosine lying 3′ to thymidine was 5.53 × 10<sup>−5</sup>, the mutation frequency at the TTTCGT motif was 5.83 × 10<sup>−4</sup> (<xref rid="F1" ref-type="fig">Fig. 1d</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref>); this motif is a subset of the consensus hotspot sequence for creating cyclobutane pyrimidine dimers<sup><xref rid="R11" ref-type="bibr">11</xref></sup>.</p>
        </sec>
        <sec id="S3">
          <title>Recurrent mutations</title>
          <p id="P6">In addition to known recurrent mutations in <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic>, we found a previously unidentified recurrent mutation in <italic toggle="yes">RAC1</italic> (ras-related C3 botulinum toxin substrate 1), a C&gt;T transition (CCT&gt;TCT) resulting in a p.Pro29Ser substitution (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 1b</xref>; designated here <italic toggle="yes">RAC1</italic><sup>P29S</sup>), in 7 of the 147 tumors. The next most frequent mutation resulted in a p.Arg630Glu substitution in DBC1 (deleted in bladder cancer 1), which we found in six melanomas. Twelve genes had four recurrences and 56 genes had three recurrences of the same missense mutation (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 4</xref>). There were 2.8-fold more recurrent nonsilent than silent mutations occurring in three or more melanomas (76 compared to 27, respectively), significantly more than expected based on a nonsynonymous to synonymous (NS:SN) ratio of 1.95 observed across all melanomas (<italic toggle="yes">P</italic> = 0.002). There were 1.97-fold more nonsilent mutations occurring in two or more melanomas, which was as expected based on the melanoma-wide NS:SN ratio (<italic toggle="yes">P</italic> = 0.75). Of note, no silent mutations recurred in more than five melanomas.</p>
        </sec>
        <sec id="S4">
          <title>Genes with high mutation burden in sun-exposed melanomas</title>
          <p id="P7">We rank ordered the genes for overall somatic mutation burden using an algorithm that incorporated the sequence context of the mutations, the gene expression status, gene-specific NS:SN ratios and mutation bias, as reflected by the silent mutation counts in each gene (<xref rid="SD1" ref-type="supplementary-material">Supplementary Note</xref>). Fifteen genes with Benjamini-Hochberg– corrected <italic toggle="yes">P</italic> values &lt;0.05 were highly ranked for mutation burden in sun-exposed melanomas (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>). The high load of mutations in <italic toggle="yes">DCC</italic>, and in particular, inactivating mutations, is unique for melanomas because this gene is commonly associated with low expression in cancer through loss of heterozygosity (LOH) or epi-genetic silencing but not with a high burden of damaging mutations<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. Although we identified mutations in <italic toggle="yes">MAPK</italic> genes (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>), none ranked high on our list, and none occurred in tumors derived from patients treated with vemurafenib or dabrafenib.</p>
          <p id="P8">Several genes encoding protein phosphatases were on the list of genes with high mutation burden. The most unique among them is <italic toggle="yes">PPP6C</italic> (protein phosphatase 6, catalytic subunit), mutations of which affected 12.4% of sun-exposed tumors (<xref rid="F2" ref-type="fig">Fig. 2</xref>), all of which also had <italic toggle="yes">BRAF</italic> or <italic toggle="yes">RAS</italic> mutations (<italic toggle="yes">P</italic> = 0.007; <xref rid="F3" ref-type="fig">Fig. 3a</xref>); two of the alterations in PPP6C, p.His92Tyr and p.Arg301Cys, were recurrent (two and four times, respectively). The <italic toggle="yes">PPP6C</italic> mutations typically clustered in or near highly conserved positions in the catalytic site and the surrounding substrate recognition area (<xref rid="F2" ref-type="fig">Fig. 2a, b</xref>). We infer that these are probable loss-of-function mutations, as they commonly occurred in the presence of LOH (in 6 of 12 tumors) (<xref rid="F3" ref-type="fig">Fig. 3a</xref>, purple) or in tumors that simultaneously had two different point mutations (3 out of 12 tumors, one of which we confirmed to have <italic toggle="yes">trans</italic> mutations using targeted sequencing of the cloned complementary DNA (cDNA)). Notably, all the double-mutant tumors included the p.Arg301Cys alteration. Another protein phosphatase, PTPRK (protein tyrosine phosphatase, receptor type, K), was altered in 19.7% of sun-exposed melanomas, with 17 different substitutions distributed throughout the coding region, including one missense mutation leading to early chain termination (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 2a, b</xref>). A third protein phosphatase, encoded by <italic toggle="yes">PTPRD</italic> (protein tyrosine phosphatase, receptor type, D), which has been reported to be mutated in other sequencing studies<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>, harbored 27 mutations in 17 tumors but ranked low on our list because of its size and high number of synonymous single-nucleotide variants (SNVs) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 2c</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>).</p>
          <p id="P9">Seven expressed genes harbored nonsense mutations, including point mutations, splice-site variants and frame-shift indels, at higher rate than would be expected by chance (Benjamini-Hochberg false discovery rate of &lt;0.05): <italic toggle="yes">DCC</italic>, <italic toggle="yes">TP53, NF1</italic>, <italic toggle="yes">ARID2</italic>, <italic toggle="yes">ZNF560, FAM58A</italic> and <italic toggle="yes">ME1</italic> (<xref rid="F3" ref-type="fig">Fig. 3b</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 7</xref>).</p>
        </sec>
        <sec id="S5">
          <title>Genes with high mutation load in sun-shielded melanomas</title>
          <p id="P10">We found three previously unidentified somatic mutations in <italic toggle="yes">DYNC1I1</italic> among 17 acral melanomas, all of which we validated by Sanger sequencing. Two <italic toggle="yes">DYNC1I1</italic> mutations were identical and resulted in the p.Arg629Cys substitution. With a mean of only ten somatic mutations per acral melanoma, the likelihood of any mutation recurring in this set by chance is extremely low. An additional melanoma of unknown origin also harbored the somatic mutation in <italic toggle="yes">DYNC1I1</italic> resulting in p.Arg629Cys (the <italic toggle="yes">DYNC1I1</italic><sup>R629C</sup> mutation), further supporting its probable importance. <italic toggle="yes">DYNC1I1</italic> encodes dynein, cytoplasmic 1, intermediate chain 1, a protein that is implicated in microtubule motor activity, progression through the spindle assembly checkpoint and possible normal chromosome segregation<sup><xref rid="R15" ref-type="bibr">15</xref></sup>.</p>
          <p id="P11">Although the highly recurrent <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation was not present in sun-shielded melanomas, we identified another mutation in <italic toggle="yes">RAC1</italic>, which resulted in the p.Asp65Asn substitution, in an acral melanoma that had a total of two somatic mutations. <italic toggle="yes">BAP1</italic> has previously been reported to be frequently mutated in uveal melanomas<sup><xref rid="R16" ref-type="bibr">16</xref></sup>. We identified one new somatic homozygous frameshift mutation in <italic toggle="yes">BAP1</italic>, resulting in early termination, among six uveal melanomas. Other mutations that we identified in sun-shielded melanomas are listed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 8</xref>.</p>
        </sec>
        <sec id="S6">
          <title>Somatic copy-number alterations</title>
          <p id="P12">We assessed somatic copy-number alterations (SCNAs) using differences in sequence coverage between all matched tumor and germline samples (sun exposed and sun shielded). The mean sequence coverage log ratios across the tumors showed large-scale genomic gains and losses in regions that were similar to those previously obtained by array comparative genome hybridization<sup><xref rid="R10" ref-type="bibr">10</xref></sup> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 3</xref>). These included copy number gains on chromosomes 1q, 6p, 7, 8q, 17q and 20q and losses on chromosomes 6q, 9p and 10. Chromosome 3 deletions in uveal melanomas, a frequent event in the metastatic state of the disease<sup><xref rid="R17" ref-type="bibr">17</xref></sup>, were also present. The CONTRA copy number program<sup><xref rid="R18" ref-type="bibr">18</xref></sup> identified 23 genomic intervals with evidence of focal copy number gains or losses (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 9</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 3b</xref>). Copy losses were in chromosomes 10q23 and 9p21, with strong deletion signals in <italic toggle="yes">PTEN</italic> and <italic toggle="yes">CDKN2A</italic>, respectively. Copy gains in chromosomes 5p13, 11q13 and 12q14 were predominantly found in mucosal and acral melanomas (<xref rid="F3" ref-type="fig">Fig. 3</xref>), as has been previously reported<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup>. We detected amplification signals in <italic toggle="yes">RICTOR</italic> on 5p13, <italic toggle="yes">CCND1</italic> (11q13) and <italic toggle="yes">CDK4</italic> (12q14) (<xref rid="F3" ref-type="fig">Fig. 3</xref>). <italic toggle="yes">ASPM</italic> (asp (abnormal spindle) homolog, micro-cephaly associated (<italic toggle="yes">Drosophila</italic>)) on 1q31 showed amplification in 11 tumors, with 9 being metastases. <italic toggle="yes">ASPM</italic> has previously been reported in metastatic melanoma and has been shown to enhance invasion<sup><xref rid="R20" ref-type="bibr">20</xref></sup>. Notably, we also identified copy gain in 7q34 (<italic toggle="yes">BRAF</italic>), supporting prior reports of <italic toggle="yes">BRAF</italic> amplification in melanoma<sup><xref rid="R7" ref-type="bibr">7</xref></sup>.</p>
        </sec>
        <sec id="S7">
          <title>Melanoma classification by mutations and SCNAs</title>
          <p id="P13">Supervised clustering according to gene mutations and SCNAs revealed three major melanoma classes. One class, comprising sun-shielded melanomas with wild-type <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic>, was characterized by a high number of copy gains and a low mutation load (<xref rid="F3" ref-type="fig">Fig. 3a</xref>). In this group, the copy gains were on chromosomes 5p13 (<italic toggle="yes">RICTOR</italic>), 11q13 (<italic toggle="yes">CCND1)</italic> and 12q14 (<italic toggle="yes">CDK4</italic>). <italic toggle="yes">RICTOR</italic> encodes a protein that forms a complex with mTOR, suggesting that the amplification on 5p13 in this group contributes to the activation of the PI3K-AKT-mTOR pathway independent of <italic toggle="yes">CDKN2A</italic> or <italic toggle="yes">PTEN</italic> copy loss. A second class comprised sun-exposed melanomas with wild-type <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic> with few copy number alterations but a high load of mutations, which typically originated in older patients (<xref rid="F3" ref-type="fig">Fig. 3a</xref>). Notably, 30% of the melanomas in this class (10 out of 33 samples) harbored deleterious mutations in <italic toggle="yes">NF1</italic> (<xref rid="F3" ref-type="fig">Fig. 3b</xref>). Furthermore, the frequent mutations in <italic toggle="yes">TP53</italic>, <italic toggle="yes">ARID2</italic> and <italic toggle="yes">PTPRK</italic> in this group suggests that inactivation of tumor suppressors is a crucial step in the pathogenesis of <italic toggle="yes">BRAF</italic>- and <italic toggle="yes">NRAS</italic>-independent melanomas. Finally, a third class of melanomas comprised sun-exposed melanomas with mutations in <italic toggle="yes">BRAF</italic> or <italic toggle="yes">NRAS</italic> with frequent copy losses in <italic toggle="yes">PTEN</italic> and/or <italic toggle="yes">CDKN2A</italic>, copy gains and point mutations in several genes, including <italic toggle="yes">PPP6C</italic> (<xref rid="F3" ref-type="fig">Fig. 3a</xref>), reinforcing the importance of additional mutations as potential modulators of MAPK-dependent melanoma tumor progression.</p>
        </sec>
        <sec id="S8">
          <title><italic toggle="yes">RAC1</italic><sup>P29S</sup> mutations</title>
          <p id="P14">We focused on <italic toggle="yes">RAC1</italic> for further evaluation because it harbored a high rate of recurrent mutation with a strong UV signature (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 1b</xref>; the TTT<underline>C</underline>CT motif is mutated 155-fold more frequently in sun-exposed than non–sun-exposed melanomas) and is highly expressed in nonmalignant and malignant melanocytes<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup>. In addition, mutations in <italic toggle="yes">RAC1</italic> are likely to be biologically relevant because RAC1 is a member of the Rho family of small GTPases (which includes CDC42) that has important roles in the control of cell proliferation, cytoskeletal reorganization and cell migration. In addition, RAC1 effectors include various protein kinases, offering the opportunity for pharmacological inhibition.</p>
          <p id="P15">We assessed the presence of the <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation using Sanger sequencing of targeted PCR-amplified products in additional specimens collected by the Specimen Core of the Yale SPORE in Skin Cancer, resulting in a total set of 364 melanomas, including 217 sun-exposed tumors. The <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation was present in 20 melanomas, all of which originated in the head, neck, limbs or upper trunk, comprising 9.2% of this type of lesion. An independent cohort of melanoma cell lines from Australia isolated from sun-exposed tumors revealed 4 out of 76 cell lines with <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutations (5.3%). There was a similar frequency of the <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation in primary (9.2%) and metastatic tumors (8.6%), which is consistent with this mutation occurring early in tumorigenesis (<xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 10</xref>). <italic toggle="yes">RAC1</italic><sup>P29S</sup> was significantly more prevalent in male patients (present in 12.8% of males compared to 2.4% of females, <italic toggle="yes">P</italic> = 0.01; <xref rid="T2" ref-type="table">Table 2</xref>), which is consistent with these mutations being induced by UV exposure, with melanoma risk increasing with UV exposure and with men having greater UV exposure<sup><xref rid="R23" ref-type="bibr">23</xref></sup> (there were threefold more head and neck melanomas in the men than in the women in our cohort) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 4a, b</xref>).</p>
          <p id="P16">The <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation was more frequent in melanomas that were wild type for both <italic toggle="yes">NRAS</italic> and <italic toggle="yes">BRAF</italic> (12.5% of melanomas with wild-type <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic> had the mutation compared to 6.2% of melanomas with mutant <italic toggle="yes">BRAF</italic> or <italic toggle="yes">NRAS</italic>) (<xref rid="T2" ref-type="table">Table 2</xref>). Among the 61 sun-exposed samples with matched normal DNA, five of six samples with <italic toggle="yes">RAC1</italic><sup>P29S</sup> also had a mutation in <italic toggle="yes">MAPK</italic> (<italic toggle="yes">P</italic> &lt; 0.01; <xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 5</xref>). <italic toggle="yes">RAC1</italic><sup>P29S</sup> was also positively associated with three of the top mutated genes in sun-exposed melanoma, in particular with <italic toggle="yes">DCC</italic>, as well as with <italic toggle="yes">CD163L1, ZNF560</italic> and <italic toggle="yes">C15orf2</italic> (<xref rid="T2" ref-type="table">Table 2</xref>). <italic toggle="yes">RAC1</italic><sup>P29S</sup> was not enriched in samples that harbored SNPs known to confer melanoma risk (Online Methods).</p>
          <p id="P17">The <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation was somatic in all cases for which matched normal DNA samples were available; <italic toggle="yes">RAC1</italic><sup>P29S</sup> is absent from the dbSNP and 1000 Genomes databases and has not been found among 2,577 germline exomes sequenced at Yale or by direct sequencing of 2,596 individuals from 57 anthropologically defined populations originating from diverse parts of the world (Online Methods).</p>
        </sec>
        <sec id="S9">
          <title>Structural analyses of RAC1<sup>P29S</sup></title>
          <p id="P18">Structural studies have shown that the switch I region of RAC1, which contains the p.Pro29Ser alteration, is a crucial regulatory element of the GTPase superfamily and is important for nucleotide binding and for interactions with effector molecules<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup>. A proline residue corresponding to RAC1 Pro29 is completely conserved in the Rho family of GTPases (with the exception of divergent RhoBTB1 and RhoBTB2)<sup><xref rid="R24" ref-type="bibr">24</xref></sup> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 6</xref>) and is located at the N terminus of the switch I loop. Previous mutagenesis studies within the RAC1 switch I loop showed that mutation of the Pro29-Gly30 pair reduces the GTPase activity of RAC1 by 50% and results in increased effector activation<sup><xref rid="R26" ref-type="bibr">26</xref></sup>.</p>
          <p id="P19">We determined two crystal structures of RAC1<sup>P29S</sup> in complex with the slowly hydrolyzing GTP analog GMP-PNP at 2.1-Å and 2.6-Å resolution and the crystal structure of wild-type RAC1 (RAC1<sup>WT</sup>) to 2.3-Å resolution (<xref rid="F4" ref-type="fig">Fig. 4</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 11</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 7</xref>). Notably, the crystal structure of RAC1<sup>P29S</sup> is conformationally distinct from that usually observed in active-state Rho family GTPases and that of RAC1<sup>WT</sup> (<xref rid="F4" ref-type="fig">Fig. 4</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Figs. 7 and 8</xref>). In the RAC1<sup>P29S</sup> crystal structure, there are direct hydrogen bonds between the ribose hydroxyl groups of GMP-PNP and the backbone carbonyls of both Ser29 and Gly30. This bonding contrasts with the pattern typically observed for Rho family GTPases, where water-mediated hydrogen bonds form between the ribose hydroxyl groups and switch I residues<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. Instead, the bonding seen in RAC1<sup>P29S</sup> closely aligns to the hydrogen bonding patterns observed in the crystal structure of activated HRAS, where direct interactions of ribose hydroxyl with the backbone are commonly present (<xref rid="F4" ref-type="fig">Fig. 4</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 7</xref>). The p.Pro29Ser alteration seems to release the conformational restraint inherent in a proline residue at position 29, therefore allowing a RAS-like altered conformation for GTP binding in the switch I loop and increased effector activation.</p>
        </sec>
        <sec id="S10">
          <title>Analyses of RAC1<sup>P29S</sup> effector binding activity</title>
          <p id="P20">RAC1 cycles between an inactive GDP-bound (GDP-RAC1) and an active GTP-bound (GTP-RAC1) form. Active RAC1 binds downstream effectors, leading to activation and membrane localization. This binding to RAC1 is mediated by the CRIB (Cdc42/Rac interactive binding) domain, which is present in several downstream effectors. We tested the binding activity of RAC1<sup>P29S</sup> and RAC1<sup>WT</sup> to two known effectors containing the CRIB domain: PAK1 (p21 protein activated kinase 1) and MLK3 (mixed-lineage kinase 3, official symbol MAP3K11). We used the canonical <italic toggle="yes">in vitro</italic> RAC1 activity assay (p21-binding domain (PBD) of PAK1 tagged to GST (GST-PAK1-PBD) and immobilized to beads) to test the binding activity of purified recombinant proteins. The binding assays showed more complex formation of pure RAC1<sup>P29S</sup> with PAK1-PBD compared to RAC1<sup>WT</sup> in the presence of GTP or slowly hydrolysable GTPγS (<xref rid="F5" ref-type="fig">Fig. 5a</xref>). Using another <italic toggle="yes">in vitro</italic> approach, we observed more complex formation between cellularly expressed MLK3 protein kinase and GTP-RAC1<sup>P29S</sup> compared to GTP- RAC1<sup>WT</sup> (<xref rid="F5" ref-type="fig">Fig. 5b</xref>). In addition, we also compared the PAK1-PBD complex formation of RAC1<sup>P29S</sup> to that of RAC1<sup>F28L</sup>, a spontaneously activated RAC1 with a p.Phe28Leu substitution, which possesses enhanced intrinsic GTP↔GDP exchange (rapidly cycling)<sup><xref rid="R27" ref-type="bibr">27</xref></sup> (<xref rid="F5" ref-type="fig">Fig. 5c</xref>). Quantization by scanning the bands with ImageJ showed that the binding activity of GTP-RAC1<sup>P29S</sup> with PAK1-PBD was similar to that of GTP-RAC1<sup>F28L</sup>, and that GTP-RAC1<sup>P29S</sup> was about 4.5-fold to ninefold more active than GTP-RAC1<sup>WT</sup>, depending on the gel analyzed (<xref rid="F5" ref-type="fig">Fig. 5</xref>, gel density). These pulldown experiments showed that <italic toggle="yes">RAC1</italic><sup>P29S</sup> is a gain-of-function mutation. Corroborating this conclusion are results from other studies showing that site-directed mutagenesis of the adjacent amino acid, resulting in p.Phe28Leu in RAC1, as well as in p.Phe28Leu in Cdc42 (Cdc42<sup>F28L</sup>) or p.Phe28Leu in Rho A (RhoA<sup>F30L</sup>), resulted in a constitutively activated GTPase and was able to transform NIH3T3 cells in culture or in nude mice<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup>, highlighting the importance of this region to RAC1 activity.</p>
        </sec>
        <sec id="S11">
          <title>Functional analyses of RAC1<sup>P29S</sup> in normal and malignant cells</title>
          <p id="P21">We then examined the cellular activity of RAC1<sup>P29S</sup> compared to RAC1<sup>WT</sup> in transiently transfected normal mouse melanocytes and COS-7 cells. Expression of RAC1<sup>P29S</sup>, but not RAC1<sup>WT</sup>, in normal melanocytes enhanced ERK phosphorylation, cell proliferation and migration (<xref rid="F6" ref-type="fig">Fig. 6a–d</xref>). Furthermore, GFP-tagged RAC1<sup>P29S</sup>, but not RAC1<sup>WT</sup>, induced strong protein accumulation in the ruffling membranes of COS-7 cells (<xref rid="F6" ref-type="fig">Fig. 6e</xref>), which is a hallmark of an activated RAC1 protein<sup><xref rid="R29" ref-type="bibr">29</xref></sup>. These findings confirm that the <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation is a gain-of-function mutation, that it activates downstream signaling, and that it alters the phenotype of melanocytes and other cells.</p>
        </sec>
      </sec>
      <sec sec-type="discussion" id="S12">
        <title>DISCUSSION</title>
        <p id="P22">Melanoma is known to be a highly heterogeneous disease with respect to histology, cytology, clinical behavior, chromosomal aberrations and mutation patterns<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup>. Our sequencing of 147 melanoma exomes, the largest number of specimens analyzed so far by this approach, reinforces these observations and sheds new light on melanoma classification and the genetics of the malignant state. In general, we show three major melanoma classes, with high, medium and low mutation count, that are likely to belong to chronically exposed, intermittently sun-exposed and sun-shielded lesions, respectively. Our data reveal a mutation spectrum that is compatible with UV-induced damage in sun-exposed melanomas. The motif TTTCGT is enriched in a large portion of the sites that are mutated three or more times in sun-exposed melanomas. This motif is a known hotspot for creating cyclobutane pyrimidine dimers and (6–4) photoproducts, as UV energy is absorbed by the A-T base pairs and transferred down the pyrimidine base stack to the cytosine of a G-C pair<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup>. The resulting dipyrimidine photoproducts are usually repaired or correctly replicated, but the remainders are the principal lesions that lead to mutations in tumors after UV exposure<sup><xref rid="R33" ref-type="bibr">33</xref></sup>. We did not detect UV damage signature mutations in acral, mucosal or ocular melanomas. The spectrum of mutations located at dipyrimidine sequences in these lesions was indistinguishable from the spectrum of mutations at non-dipyrimidine sequences. This result is in agreement with data from one study<sup><xref rid="R9" ref-type="bibr">9</xref></sup> but is in disagreement with those from another group<sup><xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup>. The discrepancy between our results and those described in the latter publications might be due to differences in approaches because that study did not report two key elements of the UV signature: the percent of total mutations that were at a dipyrimidine and the percent of C&gt;T transitions that were at a dipyrimidine. The investigators reported that 60% of all mutations in acral melanomas were C&gt;T transitions, but this is at the low end for UV-induced mutations (typically 60–80%) and suggests that UV exposure might not be the only mutagen acting on this type of tumor.</p>
        <p id="P23">The strength of our sequencing a large number of melanomas is in the discovery of new genes and pathways contributing to melanoma pathogenesis. For example, we identified <italic toggle="yes">ARID2</italic> as a putative new tumor suppressor for melanomas. ARID2 is part of the SWI/SNF chromatin-remodeling complex, suggesting that these types of mutations disrupt normal chromatin function and gene expression. <italic toggle="yes">ARID2</italic> loss-of-function mutations were recently identified in hepatocellular carcinoma<sup><xref rid="R36" ref-type="bibr">36</xref></sup>.</p>
        <p id="P24">The high mutation load in several protein phosphatases, including PTPRK, PTPRD and PPP6C, is likely to release constraints on downstream targets. For example, mutations in <italic toggle="yes">PTPRK</italic>, a TGF-β target gene<sup><xref rid="R37" ref-type="bibr">37</xref></sup>, may disrupt the growth-suppressive signaling of TGF-β in the affected tumors. The newly identified alterations in the serine/threonine phosphatase PPP6C are of particular interest because the amino acid substitutions clustered in the active site of the enzyme, are likely to be inactivating and occurred exclusively in tumors with activating mutations in <italic toggle="yes">BRAF</italic> or <italic toggle="yes">NRAS</italic>. The recurrent alteration p.Arg301Cys was recently also identified in 2, and the p.Ser307Leu alteration was identified in 1, of 25 metastatic melanomas<sup><xref rid="R9" ref-type="bibr">9</xref></sup>. About 80% of nevi harbor the <italic toggle="yes">BRAF</italic> mutation resulting in p.Val600Glu and, in some cases, a <italic toggle="yes">NRAS</italic> mutation at Gln61, yet nevi are typically associated with low proliferative activity and only infrequently progress to melanoma<sup><xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup>. It is assumed that activating mutations in <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic> initiate the proliferative process that is followed by senescence, termed oncogene-induced senescence. Loss of PTEN, a dual specificity protein tyrosine phosphatase, was until now considered the major mechanism for abrogating oncogene-induced senescence in either <italic toggle="yes">BRAF</italic> or <italic toggle="yes">NRAS</italic> mutant cells through activation of the PI3K-AKT signaling pathways<sup><xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R41" ref-type="bibr">41</xref></sup>. Our data suggest a new cooperative pathway for transforming <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic> mutant melanocytes. So far, PPP6C has not been demonstrated to be part of the MAPK or PI3K-AKT pathway but rather to have a crucial role in mitotic spindle and chromosome segregation<sup><xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup>, as well as in the response to DNA strand breaks<sup><xref rid="R44" ref-type="bibr">44</xref></sup>. A known substrate of PPP6C is Aurora A, a serine/threonine kinase that controls spindle pole formation, centro-some maturation, chromosomal segregation and cytokinesis during mitosis<sup><xref rid="R42" ref-type="bibr">42</xref></sup>. As inactivation of PPP6C may lead to stimulation of the kinase activity of Aurora A, pharmacologic inhibition of Aurora A’s kinase activity might be considered. Indeed, a small-molecule inhibitor of Aurora A kinase has been already developed<sup><xref rid="R45" ref-type="bibr">45</xref></sup>, has shown a cytotoxic effect on several types of cancer cells, such as breast and glioma<sup><xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R47" ref-type="bibr">47</xref></sup>, and is being considered for clinical application, especially in combination with other drugs<sup><xref rid="R48" ref-type="bibr">48</xref></sup>.</p>
        <p id="P25">In the oncogene class, a key finding was the discovery of <italic toggle="yes">RAC1</italic><sup>P29S</sup> as a recurrent UV-signature mutation in 9.2% of sun-exposed melano-mas. In our cohort, <italic toggle="yes">RAC1</italic><sup>P29S</sup> was the third most frequent activating mutation after those of <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS. RAC1</italic><sup>P29S</sup> was predominant in male patients known to have more outdoor exposure than females<sup><xref rid="R23" ref-type="bibr">23</xref></sup>. This gender difference was unique to <italic toggle="yes">RAC1</italic><sup>P29S</sup>, and we did not find it for mutations in <italic toggle="yes">BRAF</italic> or <italic toggle="yes">NRAS</italic>. Whereas <italic toggle="yes">BRAF</italic> mutations are often in sites that are not chronically exposed to the sun, the specific types of melanoma that have a high frequency of <italic toggle="yes">NRAS</italic> mutations has not yet been determined<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup>. RAC1<sup>P29S</sup> has increased binding to PAK1 and MLK3, provides a proliferative and migratory advantage to normal melanocytes through activation of ERK, and induces membrane ruffling. It was previously reported that MLK3 is capable of recruiting a BRAF-RAF1 complex<sup><xref rid="R49" ref-type="bibr">49</xref></sup>, suggesting that MLK3 may function as a link between RAC1 and the MAP kinase cascade.</p>
        <p id="P26">Our gene association analysis showed that the <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation in the matched melanomas was frequently associated with mutations in <italic toggle="yes">DCC,</italic> a gene that was recently validated as a tumor suppressor in mouse models<sup><xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref></sup>. DCC is the netrin 1 receptor that, in the presence of the ligand, mediates positive signals for proliferation, migration and differentiation through RAC1 and CDC42 and mediates apop-tosis in the absence of ligand<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. It is possible that activating <italic toggle="yes">RAC1</italic> mutations and loss of <italic toggle="yes">DCC</italic> cooperate in promoting the malignant process in a manner analogous to the combination of <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic> mutations with loss of <italic toggle="yes">PTEN</italic> or <italic toggle="yes">PPP6C</italic>. The <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation has been recently reported in 1 out of 74 squamous cell carcinomas of the head and neck<sup><xref rid="R52" ref-type="bibr">52</xref></sup>, in 1 out of 26 esophageal cancers and 1 out of 44 pancreatic cancers<sup><xref rid="R53" ref-type="bibr">53</xref></sup>, suggesting a role for this mutation in other cancers as well.</p>
        <p id="P27">The <italic toggle="yes">in vivo</italic> biological importance of RAC1 is supported by studies with mice showing that targeted deletion of <italic toggle="yes">Rac1</italic> in melanoblasts causes defects in migration, cell-cycle progression and cytokine-sis<sup><xref rid="R54" ref-type="bibr">54</xref></sup>, and mice lacking Prex1, a Rac-specific Rho GTPase guanine nucleotide exchange factor, have defects in melanoblast migration during development and are resistant to metastasis when crossed to a mouse model of melanoma<sup><xref rid="R55" ref-type="bibr">55</xref></sup>. In our matched cohort of sun-exposed melanomas, <italic toggle="yes">PREX2</italic> harbored 20 mutations in 13 samples, none of which overlapped with those in the published report<sup><xref rid="R9" ref-type="bibr">9</xref></sup>. However, this gene did not reach high priority here because it is not expressed in normal or malignant melanocytes, it had seven silent SNVs in seven samples and it is relatively large (4,889 bases in the capture region). Nonexpressed genes may harbor a large number of mutations based on empirical data on mutation load in expressed and nonexpressed genes<sup><xref rid="R6" ref-type="bibr">6</xref></sup>.</p>
        <p id="P28">Gain-of-function mutations have proved to be productive therapeutic targets in a variety of cancers. Collectively, our findings suggest that inhibitors of direct effectors of RAC1, such as members of the PAK family of protein kinases, might be of therapeutic benefit in the treatment of melanomas.</p>
        <sec id="S13">
          <title>URLs</title>
          <p id="P29">BLAST, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://blast.ncbi.nlm.nih.gov/Blast.cgi">http://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link>; the full list of mutations is posted on MelaGrid, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://data.melagrid.org/en/dataset/exome-variants-in-melanoma">http://data.melagrid.org/en/dataset/exome-variants-in-melanoma</ext-link>.</p>
        </sec>
      </sec>
      <sec id="S15" specific-use="web-only">
        <title>ONLINE METHODS</title>
        <sec id="S16">
          <title>Melanoma tumors and cell cultures</title>
          <p id="P31">The melanoma tumors were from different patients and were excised to alleviate tumor burden. Specimens were collected with participants’ informed signed consent according to Health Insurance Portability and Accountability Act (HIPAA) regulations with a Human Investigative Committee protocol. The melanomas used for sequencing were from snap-frozen tumors or from short-term cultures<sup><xref rid="R59" ref-type="bibr">59</xref></sup>. Most of the melanoma cells were collected after 0–4 passages in culture, except for one sample called ‘YURIF’ that was collected after 14 passages in culture.</p>
        </sec>
        <sec id="S17">
          <title>Exome capture, high-throughput sequencing and sequence validation</title>
          <p id="P32">The DNeasy purification kit (QIAGEN) was used to extract genomic DNA from cell pellets and freshly frozen tumors. The OneStep PCR Inhibitor Removal Kit (Zymo Research Corporation) was used for samples with high melanin content. Whole exomes were enriched from genomic DNA by the solution-based SeqCap EZ Exome Library capture method following the manufacturer’s protocols (Roche/NimbleGen) at the Yale Center for Genome Analysis. Sequencing was performed with the Illumina Genome Analyzer (GA) IIx (56 tumor sample and 26 normal samples) and the Illumina HiSeq 2000 (91 tumor samples and 73 normal samples) as 75-bp paired-end reads following the manufacturer’s protocols. The exome capture area comprised 22,448,951 bases in the coding regions of 15,714 genes.</p>
          <p id="P33">We validated the mutation data by Sanger sequencing of 300 gene-specific amplicons (primer pairs provided on request). The frequency of the recurrent <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation was assessed using Sanger sequencing and the TaqMan assay (Applied Biosystems). A TaqMan assay to detect the <italic toggle="yes">RAC1</italic><sup>P29S</sup> mutation was designed using the Applied Biosystems software on their website. Samples from 2,596 individuals from 57 anthropologically defined populations originating from diverse parts of the world<sup><xref rid="R60" ref-type="bibr">60</xref></sup> were genotyped. Analyses were done in 384-well plates using the manufacturer’s protocol, except that volume was reduced to 3 μl. After 30 cycles, the plates were read on an AB 9600HD using SDS software.</p>
          <p id="P34">In addition, another cohort of 76 melanoma cell lines in the Oncogenomics Laboratory, Queensland Institute of Medical Research was tested by Sanger sequencing using BigDye Terminator v3.1 chemistry on a 3730xl DNA Analyzer (Applied Biosystems). The primers used are provided in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 12</xref>.</p>
        </sec>
        <sec id="S18">
          <title>Gene expression</title>
          <p id="P35">Whole-genome gene expression was derived from hybridization to NimbleGen human whole-genome microarrays, as described<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R61" ref-type="bibr">61</xref></sup>. Genes with a median expression value of 550 and above were called ‘expressed’. RNA sequencing (RNA-Seq) was performed on two independent cultures of normal human melanocytes derived from newborn foreskins and adult skin. Final RNA-Seq libraries were sequenced at 75 bp per sequence using a GAIIx Illumina sequencer. Expression of a RefSeq transcript was determined by summing up all reads across the exons of the transcript. The transcript length-normalized and log-transformed value was used as the measure of gene expression. A two-component Gaussian mixture model was fit to the data, and a lower bound for expressed genes was chosen as two s.d. away from the higher distribution mean. For more details, see the <xref rid="SD1" ref-type="supplementary-material">Supplementary Note</xref>.</p>
        </sec>
        <sec id="S19">
          <title>Reference genome and RefSeq database</title>
          <p id="P36">We used the human reference genome GRCh37/hg19 for mapping exome-sequencing (Exome-Seq) and RNA-Seq data. The RefSeq sequence database downloaded from NCBI on 12 May 2011 was used as our gene model and for determining amino acid substitutions.</p>
        </sec>
        <sec id="S20">
          <title>Exome-Seq processing</title>
          <sec id="S21">
            <title>Read mapping and somatic calling</title>
            <p id="P37">The following procedure was used to call melanoma sequence variations: reads were first trimmed based on their quality scores using the program BTrim<sup><xref rid="R62" ref-type="bibr">62</xref></sup>. The reads were then mapped against the reference genome using bwa<sup><xref rid="R63" ref-type="bibr">63</xref></sup>. SAMtools version 0.1.8–11 (r672)<sup><xref rid="R64" ref-type="bibr">64</xref></sup> was used for PCR duplicate removal and SNV calling. Annotations of SNVs were performed with MU2A<sup><xref rid="R65" ref-type="bibr">65</xref></sup>. Annotation files were checked for adjacent pairs of SNVs affecting the same codon. If present, sequencing reads were scanned for the occurrence of both SNVs on a single allele, and the amino acid change was predicted based on the simultaneous mutations. SNVs were filtered according to the following quality criteria: (i) mutant allele frequency ≥13%; (ii) SAMtools mapping score ≥40; (iii) at least one forward and one backward read; (iv) a minimum coverage of four mutant and eight total reads at the variant position; and (v) uniform mapping of reads with the variant allele across the SNV locus. SNVs were further filtered based on their presence in repositories of common variations (dbSNP135 and 2,577 noncancer exomes sequenced at Yale). An SNV was called somatic in the absence of variant reads in the germline DNA samples, tolerating one mutant read in the normal samples, and expecting a sufficient variant to total read ratio in tumor and normal samples as assessed by Fisher’s exact test (<italic toggle="yes">P</italic> value threshold of 0.001).</p>
            <p id="P38">We used SAMtools for indel calling, implementing strict selection criteria, including indel allele frequency &gt;0.1, minimal SNP score of 250 in at least one melanoma and absence from repositories of common variations (dbSNP135 and 2,577 noncancer exomes sequenced at Yale). To identify somatic indels, we first excluded all indels that were also present in our normal samples and, in the absence of an indel call in the normal samples, we required a sequence coverage of at least eight independent reads at the corresponding position in the normal samples.</p>
          </sec>
          <sec id="S22">
            <title>LOH calculation</title>
            <p id="P39">To determine LOH in matched samples pairs, we followed a similar approach to that previously described<sup><xref rid="R66" ref-type="bibr">66</xref></sup>. We identified heterozygous positions in normal samples and used the R module ‘DNACopy’ to perform circular binary segmentation. The resulting regions were filtered for region-wide LOH.</p>
          </sec>
          <sec id="S23">
            <title>Somatic copy number analysis</title>
            <p id="P40">The sequence coverage log fold change was visualized in IGV<sup><xref rid="R67" ref-type="bibr">67</xref></sup>. We used the CONTRA copy number analysis program<sup><xref rid="R18" ref-type="bibr">18</xref></sup> to determine SCNAs in the matched melanoma samples. The program was run with default parameters, excluding multimapped reads. We counted the number of samples for which at least one exon in a gene had a significant CONTRA call and fitted a Poisson distribution to the resulting sample counts per gene. Genes that had SCNA events in significantly more samples than expected were retained. We additionally required that these genes were located in chromosomal bands with significant CMDS calls, as previously described<sup><xref rid="R68" ref-type="bibr">68</xref>,<xref rid="R69" ref-type="bibr">69</xref></sup>.</p>
          </sec>
          <sec id="S24">
            <title>Testing RAC1 for associations with melanoma risk SNPs, MAPK genes and genes with high mutation burden</title>
            <p id="P41">We tested the melanoma risk SNPs rs1800401, rs1800407 (both in <italic toggle="yes">OCA2</italic>), rs16891982 (<italic toggle="yes">SLC45A2</italic>), rs1801516 (<italic toggle="yes">ATM</italic>) and rs1126809 (<italic toggle="yes">TYR</italic>), all of which are located in the exome capture area, for association with <italic toggle="yes">RAC1</italic> mutations using the Fisher’s exact test. We proceeded similarly for assessing the association of <italic toggle="yes">RAC1</italic> mutations with <italic toggle="yes">MAP</italic>K genes, as well as for genes with high mutation burden.</p>
          </sec>
        </sec>
        <sec id="S25">
          <title>Cloning and analysis of double-mutant <italic toggle="yes">PPP6C</italic> in melanoma cells</title>
          <p id="P42">Total RNA was extracted from YUGANK melanoma cells carrying the double <italic toggle="yes">PPP6C</italic> mutations resulting in p.Gln220X and p.Arg301Cys using an RNeasy Mini Kit (QIAGEN). cDNA was constructed using Superscript III Reverse Transcriptase following the manufacturer’s instructions (Invitrogen). The region containing the p.Gln220X and p.Arg301Cys alterations was PCR amplified (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 12</xref>), and the 494-bp fragments were cloned into the pCR4-TOPO TA cloning vector (Invitrogen). One Shot TOP10 (Invitrogen) competent <italic toggle="yes">Escherichia coli</italic> cells were transformed with the TOPO cloning reaction following the manufacturer’s instructions. Transformants were analyzed by colony PCR using M13 primers. PCR reactions were cleaned with ExoSAP-IT (Affymetrix) and Sanger sequenced with T3 and T7 primers.</p>
        </sec>
        <sec id="S26">
          <title>Site-directed mutagenesis and transient ectopic <italic toggle="yes">RAC1</italic> expression</title>
          <p id="P43">The pBabe-CyPet-<italic toggle="yes">RAC1</italic> retroviral expression vector and the pcDNA3-<italic toggle="yes">eGFP</italic>-<italic toggle="yes">RAC1</italic> plasmid were purchased from Addgene. The plasmids were constructed by K.M. Hahn<sup><xref rid="R70" ref-type="bibr">70</xref>–<xref rid="R72" ref-type="bibr">72</xref></sup>, who deposited them in Addgene for distribution. The CyPet tag is cleaved from RAC1 in mouse melanocytes, as observed before in neutrophils (K.M. Hahn, personal communication).</p>
          <p id="P44">The p.Pro29Ser alteration was introduced in each of the plasmids with the QuikChange Kit (Stratagene). The alteration in the vector was validated by sequencing the plasmids. The primers used are provided in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 12</xref>.</p>
          <p id="P45">Mouse melanocytes (from C57BL mice) at passage 19 were infected with retroviruses encoding pBabe-CyPet-<italic toggle="yes">RAC1</italic><sup>WT</sup> or <italic toggle="yes">RAC1</italic><sup>P29S</sup>. Puromycin (1 μg/ml) was added 2 d later, and the melanocytes were tested for cell proliferation and migration after 10 d of selection with the drug.</p>
        </sec>
        <sec id="S27">
          <title>Fluorescence microscopy</title>
          <p id="P46">COS-7 cells were transiently transfected with 1.5 μg pcDNA3-<italic toggle="yes">eGFP-RAC1</italic><sup>WT</sup> and <italic toggle="yes">RAC1</italic><sup>P29S</sup> constructs using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. After transfection, cells were plated in 24-well trays on Fisherbrand number 1.5 coverslips (12-545-81), and after 1 d of culture in DMEM supplemented with 10% FBS (PBS) and 1% penicillin and streptomycin, were washed, fixed with paraformalde-hyde (3.2%) and washed again, and coverslips were mounted onto microscope slides using ProLong Gold antifade mountant (Invitrogen, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="P36935">P36935</ext-link>). Cells were examined with a multicolor spinning-disk confocal UltraVIEW VoX system (PerkinElmer) based on an inverted Olympus microscope (1X-71) equipped with a 1 Kb × 1 Kb electromagnetic charge-coupled device camera (Hamamatsu Photonics) using a 60× 1.4 numerical aperture (NA) oil objective lens. The system was controlled by Velocity software.</p>
        </sec>
        <sec id="S28">
          <title>Western blot analyses</title>
          <p id="P47">Total cell extracts (16 μg protein per lane) with concentrations estimated with the Bio-Rad kit (Bio-Rad Laboratories) were subjected to western blot analysis<sup><xref rid="R21" ref-type="bibr">21</xref></sup>. The membranes were probed with the mouse monoclonal antibody against recombinant full-length RAC1 protein (23A8, Millipore 05-389), monoclonal antibody to Erk1/2 phosphorylated at Thr202 and Tyr204 (Erk1/2 (Thr202/Tyr204), ERK1/2 (ERK1/2, 137F5) (both from Cell Signaling Technology) and monoclonal antibody to β-actin (A1978, Sigma-Aldrich). All antibodies were used at 1:1,000 dilution.</p>
        </sec>
        <sec id="S29">
          <title>Cell proliferation and migration assays</title>
          <p id="P48">Cell proliferation assays were performed in 6-well plates (~2,000 cells per well) in triplicate wells in OptiMEM supplemented with antibiotics and 7% horse serum in the presence of the required growth factor TPA (10 ng/ml, 12-<italic toggle="yes">O</italic>-tetradecanoylphorbol-13-acetate, Sigma) and puromycin (1 μg/ml). The cells were harvested at 2-d intervals and counted with a Coulter counter.</p>
          <p id="P49">Cell migration was measured with the Cultrex 24-Well Cell Migration Assay (Trevigen, 3465-024-K) following the manufacturer’s instructions and as described<sup><xref rid="R59" ref-type="bibr">59</xref></sup>.</p>
        </sec>
        <sec id="S30">
          <title>RAC1<sup>WT</sup> and RAC1<sup>P29S</sup> expression and purification</title>
          <p id="P50">RAC1<sup>P29S</sup> spanning residues 2–177 was subcloned into a modified pET-28 vector with a six- histidine N-terminal tag followed by GST and thrombin cleavage site. Recombinant RAC1<sup>P29S</sup> was expressed as an N-terminal fusion protein with glutathione-S-transferase (GST) in BL21(DE3) cells and induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 12 h at 30 °C. The fusion protein was affinity purified and cleaved by thrombin at 4 °C overnight. The protein was then loaded on a Superdex 200 HiLoad 16/60 (GE Healthcare) column in a buffer of 20 mM Tris-HCl (pH 8.0), 150 mM NaCl and 1 mM dithiothreitol (DTT). Purified mutant protein was finally concentrated to 3.5 mg/ml in a buffer of 20 mM Tris, 150 mM NaCl, 1 mM DTT and 5 mM MgCl<sub>2</sub> with and without 1 mM GMP-PNP.</p>
          <p id="P51">For RAC1<sup>WT</sup>, we subcloned residues 2–177 into a modified pET-28 vector with a six-histidine N-terminal tag. RAC1<sup>WT</sup> was expressed as an N-terminal fusion in BL21(DE3) cells and induced with 1 mM IPTG for 12 h at 30 °C. Briefly, RAC1<sup>WT</sup> was affinity purified and loaded on a Superdex 75 (GE Healthcare) column in a buffer of 20 mM Tris-HCl (pH 8.0), 150 mM NaCl and 1 mM DTT. Purified RAC1<sup>WT</sup> was finally concentrated to 7 mg/ml in a buffer of 20 mM Tris, 150 mM NaCl, 1 mM DTT, 5 mM MgCl<sub>2</sub> and 1 mM GMP-PNP.</p>
        </sec>
        <sec id="S31">
          <title>RAC1<sup>P29S</sup> and RAC1<sup>WT</sup> crystallization</title>
          <p id="P52">Crystals of RAC1<sup>P29S</sup> were grown by vapor-diffusion hanging drops formed by mixing a 1:1 volume ratio of purified RAC1<sup>P29S</sup> and reservoir solution containing 0.1 M 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES) (pH 7.5), 20% (v/v) PEG 4,000 and 7% (v/v) isopropanol at room temperature. RAC1<sup>P29S</sup> crystals belong to space group <italic toggle="yes">P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> with unit cell dimensions a = 50.3 Å, b = 80.0 Å, c = 94.9 Å and α, β, γ = 90°. There were two molecules per asymmetric unit. Crystals were equilibrated in a cryoprotectant buffer containing reservoir buffer plus 30% (v/v) ethylene glycol and were flash frozen in a nitrogen stream at 100 K. X-ray data from a single crystal were collected to 2.1-Å resolution at the Yale Chemical and Biophysical Instrumentation Center using a Rigaku HF007 generator and a Saturn 944+ CCD detector.</p>
          <p id="P53">A second crystal form was determined to 2.6-Å resolution from identical crystallization conditions in the space group <italic toggle="yes">P</italic>22<sub>1</sub>2<sub>1</sub> with unit cell dimensions a = 40.6 Å, b = 51.9 Å, c = 99.3 Å and α, β, γ = 90°. This crystal form has similar packing to the <italic toggle="yes">P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> crystal and is conformationally similar (root mean square deviation (r.m.s.d.) values of 0.5 Å and 0.3 Å over 177 and 176 Cα atoms when compared to chains A and B, respectively), so we conducted our analyses using the <italic toggle="yes">P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> crystal.</p>
          <p id="P54">Crystals of RAC1<sup>WT</sup> were grown in almost identical conditions in the space group <italic toggle="yes">P</italic>2<sub>1</sub> with unit cell dimensions a = 40.9 Å, b = 97.9 Å, c = 51.7 Å and β = 96.6°. This crystal form has similar packing to both of the RAC1<sup>P29S</sup> crystals, allowing us to investigate whether the conformational changes observed for RAC1<sup>P29S</sup> were caused by crystal packing (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 8</xref>).</p>
        </sec>
        <sec id="S32">
          <title>Structure determination and refinement</title>
          <p id="P55">For the RAC1<sup>P29S</sup>
<italic toggle="yes">P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> crystal form, data were processed using the HKL2000 package<sup><xref rid="R73" ref-type="bibr">73</xref></sup>, and the initial phases were calculated by molecular replacement using the program Phaser<sup><xref rid="R74" ref-type="bibr">74</xref>,<xref rid="R75" ref-type="bibr">75</xref></sup>. Wild-type RAC1 (PDB 1MH1)<sup><xref rid="R75" ref-type="bibr">75</xref></sup> was used as a search model and yielded translation <italic toggle="yes">Z</italic>-scores of 19.2 and 47.1 for the two molecules in the asymmetric unit. Automated model building with ARP/wARP<sup><xref rid="R76" ref-type="bibr">76</xref></sup> built residues 2–176 in molecule A and residues 3–175 in molecule B, thus avoiding potential problems with model bias. Cycles of refinement and manual model building were conducted using REFMAC5<sup><xref rid="R77" ref-type="bibr">77</xref></sup> with a maximum-likelihood target, two TLS (Translation/Libration/Screw) groups per molecule and medium NCS (non-crystallographic symmetry) using COOT<sup><xref rid="R78" ref-type="bibr">78</xref></sup>. Model validation was conducted using MolProbity<sup><xref rid="R79" ref-type="bibr">79</xref></sup>. The final refined model of RAC1<sup>P29S</sup> had <italic toggle="yes">R</italic> and <italic toggle="yes">R</italic><sub>free</sub> values of 24.0% and 28.5%, respectively (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 8</xref>). All of the residues fell within favored or allowed regions of the Ramachandran plot. Good electron density was observed throughout the structure, including for GMP-PNP and the switch I region (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 8a, b</xref>). The structure is deposited in PDB under accession code 3SBD.</p>
          <p id="P56">A similar processing, solution and refinement protocol was conducted for the 2.6-Å <italic toggle="yes">P</italic>22<sub>1</sub>2<sub>1</sub> structure of RAC1<sup>P29S</sup> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 10</xref>), and the data have been deposited in PDB under accession code 3SBE. Good electron density was observed throughout this structure, including for GMP-PNP and the switch I region.</p>
          <p id="P57">A similar processing, solution and refinement protocol was conducted for the 2.3-Å <italic toggle="yes">P</italic>2<sub>1</sub> structure of RAC1<sup>WT</sup> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 10</xref>), and the data have been deposited in PDB under accession code 3TH5. Good electron density was observed throughout this structure, including for GMP-PNP; however, the switch I regions of both molecules in the asymmetric unit were not well defined (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 8c</xref>). For molecule A, the switch I loop had poor electron density, and for molecule B, the switch I loop was not visible in the electron density. The crystal structure of RAC1<sup>WT</sup> has similar lattice interfaces as RAC1<sup>P29S</sup>, illustrating that the conformational differences observed in switch I are not the result of crystal packing effects.</p>
          <p id="P58">Overall, the two RAC1<sup>WT</sup> molecules are globally similar to the RAC1<sup>P29S</sup> structures (molecule A has r.m.s.d. values of 0.44 Å, 0.31 Å and 0.34 Å over 173, 173 and 174 residues, respectively, when compared to the <italic toggle="yes">P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> A, B and <italic toggle="yes">P</italic>22<sub>1</sub>2<sub>1</sub> crystals; and molecule B has r.m.s.d. values of 0.39 Å, 0.35 Å and 0.43 Å over 170, 169 and 171 residues, respectively, when compared to the <italic toggle="yes">P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> A, B and <italic toggle="yes">P</italic>22<sub>1</sub>2<sub>1</sub> crystals).</p>
        </sec>
        <sec id="S33">
          <title>RAC1 activity assays</title>
          <p id="P59">Two independent approaches were used to assess the activity of RAC1<sup>P29S</sup> compared to RAC1<sup>WT</sup>. The traditional PAK1 pulldown assay (Millipore, RAC1 activation assay kit) was used with recombinant N-terminal His-tagged RAC1<sup>WT</sup> and RAC1<sup>P29S</sup> purified by affinity and size exclusion, as previously described<sup><xref rid="R80" ref-type="bibr">80</xref></sup>. The proteins were dialyzed for 12 h against buffer containing 20 mM Tris-HCl (pH 8.0), 0.15 M NaCl, 1 mM DTT and 10 mM EDTA, followed by 2× dialysis for 12 h against the same buffer without EDTA to discharge innately bound nucleotides<sup><xref rid="R80" ref-type="bibr">80</xref></sup>. His-RAC1<sup>WT</sup> and His-RAC1<sup>P29S</sup> (6 μg) were incubated with 1 mM of nucleotide and GST-PAK1-PBD (GST fusion protein corresponding to residues 67–150 the p21-binding domain (PBD), of human PAK1 bound to glutathione-Sepharose beads) (5 μg) for 3 h at 4 °C in a buffer containing 20 mM Tris-HCl (pH 8.0), 0.15 M NaCl, 1 mM DTT and 10 mM MgCl<sub>2</sub>. The beads were sedimented by centrifugation, the pellets were washed 3× with the same buffer, and the bound proteins were eluted with SDS sample buffer at 95 °C and analyzed by western blot with polyhistidine antibody (HIS-1, H1029, Sigma-Aldrich) at 1:1,000- dilution. Incubations included no addition, GDP, GTP or GTPγS. NC (negative control) indicates GST-PAK1-PBD without any loaded RAC1 protein. One microgram of His-RAC1<sup>WT</sup> and His-RAC1<sup>P29S</sup> were included as controls. In addition, the ‘fast-cycling’ p.Phe28Leu alteration was introduced to His-RAC1<sup>WT</sup> by site-directed mutagenesis (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 12</xref>). We then tested the PAK1-PBD binding activity of His-RAC1<sup>WT</sup>, His-RAC1<sup>P29S</sup> and His-RAC1<sup>F28L</sup> purified proteins (1 μg of each) following the manufacturer’s procedure.</p>
          <p id="P60">Alternatively, we performed RAC1 pulldown experiments to assess the binding of RAC1 to MLK3 in melanoma cell lysates. MLK3 contains a CRIB motif that interacts with a cloned construct of RAC1 in a two-hybrid system<sup><xref rid="R81" ref-type="bibr">81</xref></sup>. In these experiments, we used immobilized His-GST–tagged proteins captured to glutathione-Sepharose from bacteria lysates following the manufacturer’s instructions without further manipulations. The bead-bound slurries of His-GST-RAC1<sup>WT</sup> and His-GST-RAC1<sup>P29S</sup> were incubated with no addition, GDP, GTP or GTPγS in 20 mM Tris, pH 8, 150 mM NaCl, 1 mM DTT and 10 mM MgCl<sub>2</sub> for 3 h on ice. The beads were then washed 3× with lysis buffer (150 mM NaCl, 10 mM HEPES, pH 7.3, 1 mM EDTA and 1% NP40, plus protease and phosphatase inhibitors) and then incubated with YULAC (RAC1<sup>WT</sup> or BRAF<sup>V600E</sup>) and YUHEF (RAC1<sup>P29S</sup> or BRAF<sup>WT</sup>) melanoma cell lysates (500 μg per assay) overnight on a rotating wheel at 8 °C. The beads were washed 3× with lysis buffer, and the bound proteins were eluted with 2× SDS sample buffer and subjected to western blotting with mouse monoclonal antibodies to MLK3 (LS-C133912, LifeSpan BioSciences) at 1:1,000 dilution.</p>
        </sec>
      </sec>
      <sec sec-type="supplementary-material" id="S34">
        <title>Supplementary Material</title>
        <supplementary-material content-type="local-data" id="SD1" position="float" orientation="portrait">
          <label>1</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS390374-supplement-1.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" id="d37e2187" position="anchor"/>
        </supplementary-material>
      </sec>
    </body>
    <back>
      <ack id="S35">
        <p>This work was supported by the Yale SPORE in Skin Cancer funded by the National Cancer Institute grant number 1 P50 CA121974 (principal investigator, R.H.), the Melanoma Research Alliance (a Team award to R.H., M.B., M.K. and D.F.S.), The National Library of Medicine Training grant 5T15LM007056 (P.E.), the Department of Dermatology (R.H.), Yale Comprehensive Cancer Center (M.K.), the National Health and Medical Research Council of Australia (N.K.H. and K.D.-R.), Gilead Sciences, Inc. (J.S., M.K., R.H. and T.J.B.) and a generous gift from Roz and Jerry Meyer (R.H., M.S. and H.M.K.). We thank C. Truini, W. Meng, B. Speed, E. Straka, A. Raefski, M. Scallion and S. Levin for technical support, P. Parsons, C. Schmidt and colleagues at the Queensland Institute of Medical Research for generously providing many of the melanoma cell lines, the Yale Center for Genome Analysis and the Northeastern Collaborative Access Team (NE-CAT) facility at the Advanced Photon Source at Argonne National Laboratory.</p>
      </ack>
      <fn-group>
        <fn id="FN2">
          <p><bold>Accession codes.</bold> Crystal structures are deposited in PDB with accession codesBD, 3SBE and 3TH5.</p>
        </fn>
        <fn id="FN3">
          <p>Note: <xref rid="SD1" ref-type="supplementary-material">Supplementary information</xref> is available in the online version of the paper.</p>
        </fn>
        <fn id="FN4" fn-type="con">
          <p>
            <bold>AUTHOR CONTRIBUTIONS</bold>
          </p>
          <p>M.K., R.H., R.P.L., J.S. and T.J.B. designed and supervised the study. Y.K., P.E., M.C., J.P.M., S. Ma, G.G. and A.C. performed the bioinformatic analyses. A.B., E.C., E.C.H., M.J.D., K.D.-R., K.K.K., N.K.H. and S. Mane collected and analyzed the melanoma samples and performed the sequencing and functional experiments. B.H.H. and T.J.B. performed the crystallographic studies. S.A., D.N., M.B., M.S., H.M.K., M.A.M. and R.S.L. provided the clinical specimens and the clinical annotation. D.E.B. and D.F.S. analyzed sun-related mutations. All authors contributed to the final version of the paper.</p>
        </fn>
        <fn id="FN5" fn-type="conflict">
          <p>
            <bold>COMPETING FINANCIAL INTERESTS</bold>
          </p>
          <p>The authors declare no competing financial interests.</p>
        </fn>
        <fn id="FN6">
          <p>Reprints and permissions information is available online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/reprints/index.html">http://www.nature.com/reprints/index.html</ext-link>.</p>
        </fn>
      </fn-group>
      <ref-list>
        <ref id="R1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bauer</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site</article-title>
            <source>Pigment Cell Melanoma Res</source>
            <volume>24</volume>
            <fpage>345</fpage>
            <lpage>351</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21324100</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-148X.2011.00837.x</pub-id>
            <pub-id pub-id-type="pmcid">PMC3107974</pub-id>
          </element-citation>
        </ref>
        <ref id="R2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bollag</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</article-title>
            <source>Nature</source>
            <volume>467</volume>
            <fpage>596</fpage>
            <lpage>599</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20823850</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature09454</pub-id>
            <pub-id pub-id-type="pmcid">PMC2948082</pub-id>
          </element-citation>
        </ref>
        <ref id="R3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chapman</surname>
                <given-names>PB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</article-title>
            <source>N Engl J Med</source>
            <volume>364</volume>
            <fpage>2507</fpage>
            <lpage>2516</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21639808</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1103782</pub-id>
            <pub-id pub-id-type="pmcid">PMC3549296</pub-id>
          </element-citation>
        </ref>
        <ref id="R4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ribas</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Flaherty</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>BRAF targeted therapy changes the treatment paradigm in melanoma</article-title>
            <source>Nat Rev Clin Oncol</source>
            <volume>8</volume>
            <fpage>426</fpage>
            <lpage>433</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21606968</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrclinonc.2011.69</pub-id>
          </element-citation>
        </ref>
        <ref id="R5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jakob</surname>
                <given-names>JA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>NRAS mutation status is an independent prognostic factor in metastatic melanoma</article-title>
            <source>Cancer</source>
            <comment>published online</comment>
            <pub-id pub-id-type="doi">10.1002/cncr.26724</pub-id>
            <day>16</day>
            <month>12</month>
            <year>2011</year>
            <pub-id pub-id-type="pmcid">PMC3310961</pub-id>
            <pub-id pub-id-type="pmid">22180178</pub-id>
          </element-citation>
        </ref>
        <ref id="R6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pleasance</surname>
                <given-names>ED</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A comprehensive catalogue of somatic mutations from a human cancer genome</article-title>
            <source>Nature</source>
            <volume>463</volume>
            <fpage>191</fpage>
            <lpage>196</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20016485</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature08658</pub-id>
            <pub-id pub-id-type="pmcid">PMC3145108</pub-id>
          </element-citation>
        </ref>
        <ref id="R7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Nikolaev</surname>
                <given-names>SI</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Exome sequencing identifies recurrent somatic <italic toggle="yes">MAP2K1</italic> and <italic toggle="yes">MAP2K2</italic> mutations in melanoma</article-title>
            <source>Nat Genet</source>
            <volume>44</volume>
            <fpage>133</fpage>
            <lpage>139</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22197931</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.1026</pub-id>
          </element-citation>
        </ref>
        <ref id="R8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wei</surname>
                <given-names>X</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Exome sequencing identifies GRIN2A as frequently mutated in melanoma</article-title>
            <source>Nat Genet</source>
            <volume>43</volume>
            <fpage>442</fpage>
            <lpage>446</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21499247</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.810</pub-id>
            <pub-id pub-id-type="pmcid">PMC3161250</pub-id>
          </element-citation>
        </ref>
        <ref id="R9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Berger</surname>
                <given-names>MF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Melanoma genome sequencing reveals frequent <italic toggle="yes">PREX2</italic> mutations</article-title>
            <source>Nature</source>
            <volume>485</volume>
            <fpage>502</fpage>
            <lpage>506</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22622578</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11071</pub-id>
            <pub-id pub-id-type="pmcid">PMC3367798</pub-id>
          </element-citation>
        </ref>
        <ref id="R10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Curtin</surname>
                <given-names>JA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Distinct sets of genetic alterations in melanoma</article-title>
            <source>N Engl J Med</source>
            <volume>353</volume>
            <fpage>2135</fpage>
            <lpage>2147</lpage>
            <year>2005</year>
            <pub-id pub-id-type="pmid">16291983</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa050092</pub-id>
          </element-citation>
        </ref>
        <ref id="R11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brash</surname>
                <given-names>DE</given-names>
              </name>
              <name name-style="western">
                <surname>Haseltine</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>UV-induced mutation hotspots occur at DNA damage hotspots</article-title>
            <source>Nature</source>
            <volume>298</volume>
            <fpage>189</fpage>
            <lpage>192</lpage>
            <year>1982</year>
            <pub-id pub-id-type="pmid">7045692</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/298189a0</pub-id>
          </element-citation>
        </ref>
        <ref id="R12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bernet</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Fitamant</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Netrin-1 and its receptors in tumour growth promotion</article-title>
            <source>Expert Opin Ther Targets</source>
            <volume>12</volume>
            <fpage>995</fpage>
            <lpage>1007</lpage>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18620521</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14728222.12.8.995</pub-id>
          </element-citation>
        </ref>
        <ref id="R13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Solomon</surname>
                <given-names>DA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma</article-title>
            <source>Cancer Res</source>
            <volume>68</volume>
            <fpage>10300</fpage>
            <lpage>10306</lpage>
            <year>2008</year>
            <pub-id pub-id-type="pmid">19074898</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-08-3272</pub-id>
            <pub-id pub-id-type="pmcid">PMC2760967</pub-id>
          </element-citation>
        </ref>
        <ref id="R14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Stark</surname>
                <given-names>MS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Frequent somatic mutations in <italic toggle="yes">MAP3K5</italic> and <italic toggle="yes">MAP3K9</italic> in metastatic melanoma identified by exome sequencing</article-title>
            <source>Nat Genet</source>
            <volume>44</volume>
            <fpage>165</fpage>
            <lpage>169</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22197930</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.1041</pub-id>
            <pub-id pub-id-type="pmcid">PMC3267896</pub-id>
          </element-citation>
        </ref>
        <ref id="R15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sivaram</surname>
                <given-names>MV</given-names>
              </name>
              <name name-style="western">
                <surname>Wadzinski</surname>
                <given-names>TL</given-names>
              </name>
              <name name-style="western">
                <surname>Redick</surname>
                <given-names>SD</given-names>
              </name>
              <name name-style="western">
                <surname>Manna</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Doxsey</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Dynein light intermediate chain 1 is required for progress through the spindle assembly checkpoint</article-title>
            <source>EMBO J</source>
            <volume>28</volume>
            <fpage>902</fpage>
            <lpage>914</lpage>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19229290</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/emboj.2009.38</pub-id>
            <pub-id pub-id-type="pmcid">PMC2670866</pub-id>
          </element-citation>
        </ref>
        <ref id="R16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Harbour</surname>
                <given-names>JW</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Frequent mutation of BAP1 in metastasizing uveal melanomas</article-title>
            <source>Science</source>
            <volume>330</volume>
            <fpage>1410</fpage>
            <lpage>1413</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">21051595</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1194472</pub-id>
            <pub-id pub-id-type="pmcid">PMC3087380</pub-id>
          </element-citation>
        </ref>
        <ref id="R17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Onken</surname>
                <given-names>MD</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma</article-title>
            <source>Clin Cancer Res</source>
            <volume>13</volume>
            <fpage>2923</fpage>
            <lpage>2927</lpage>
            <year>2007</year>
            <pub-id pub-id-type="pmid">17504992</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-06-2383</pub-id>
          </element-citation>
        </ref>
        <ref id="R18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>CONTRA: copy number analysis for targeted resequencing</article-title>
            <source>Bioinformatics</source>
            <volume>28</volume>
            <fpage>1307</fpage>
            <lpage>1313</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22474122</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts146</pub-id>
            <pub-id pub-id-type="pmcid">PMC3348560</pub-id>
          </element-citation>
        </ref>
        <ref id="R19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Whiteman</surname>
                <given-names>DC</given-names>
              </name>
              <name name-style="western">
                <surname>Pavan</surname>
                <given-names>WJ</given-names>
              </name>
              <name name-style="western">
                <surname>Bastian</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin</article-title>
            <source>Pigment Cell Melanoma Res</source>
            <volume>24</volume>
            <fpage>879</fpage>
            <lpage>897</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21707960</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-148X.2011.00880.x</pub-id>
            <pub-id pub-id-type="pmcid">PMC3395885</pub-id>
          </element-citation>
        </ref>
        <ref id="R20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kabbarah</surname>
                <given-names>O</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrative genome comparison of primary and metastatic melanomas</article-title>
            <source>PLoS ONE</source>
            <volume>5</volume>
            <fpage>e10770</fpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20520718</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0010770</pub-id>
            <pub-id pub-id-type="pmcid">PMC2875381</pub-id>
          </element-citation>
        </ref>
        <ref id="R21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Koga</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genome-wide screen of promoter methylation identifies novel markers in melanoma</article-title>
            <source>Genome Res</source>
            <volume>19</volume>
            <fpage>1462</fpage>
            <lpage>1470</lpage>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19491193</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.091447.109</pub-id>
            <pub-id pub-id-type="pmcid">PMC2720187</pub-id>
          </element-citation>
        </ref>
        <ref id="R22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Halaban</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications</article-title>
            <source>PLoS ONE</source>
            <volume>4</volume>
            <fpage>e4563</fpage>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19234609</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0004563</pub-id>
            <pub-id pub-id-type="pmcid">PMC2642998</pub-id>
          </element-citation>
        </ref>
        <ref id="R23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fears</surname>
                <given-names>TR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk</article-title>
            <source>Cancer Res</source>
            <volume>62</volume>
            <fpage>3992</fpage>
            <lpage>3996</lpage>
            <year>2002</year>
            <pub-id pub-id-type="pmid">12124332</pub-id>
          </element-citation>
        </ref>
        <ref id="R24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wennerberg</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Rossman</surname>
                <given-names>KL</given-names>
              </name>
              <name name-style="western">
                <surname>Der</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>The Ras superfamily at a glance</article-title>
            <source>J Cell Sci</source>
            <volume>118</volume>
            <fpage>843</fpage>
            <lpage>846</lpage>
            <year>2005</year>
            <pub-id pub-id-type="pmid">15731001</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.01660</pub-id>
          </element-citation>
        </ref>
        <ref id="R25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hakoshima</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Shimizu</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Maesaki</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Structural basis of the Rho GTPase signaling</article-title>
            <source>J Biochem</source>
            <volume>134</volume>
            <fpage>327</fpage>
            <lpage>331</lpage>
            <year>2003</year>
            <pub-id pub-id-type="pmid">14561717</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jb/mvg149</pub-id>
          </element-citation>
        </ref>
        <ref id="R26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ménard</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Snyderman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Role of phosphate-magnesium–binding regions in the high GTPase activity of rac1 protein</article-title>
            <source>Biochemistry</source>
            <volume>32</volume>
            <fpage>13357</fpage>
            <lpage>13361</lpage>
            <year>1993</year>
            <pub-id pub-id-type="pmid">8241192</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi00211a050</pub-id>
          </element-citation>
        </ref>
        <ref id="R27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Reinstein</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Schlichting</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Frech</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Goody</surname>
                <given-names>RS</given-names>
              </name>
              <name name-style="western">
                <surname>Wittinghofer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>p21 with a phenylalanine 28→leucine mutation reacts normally with the GTPase activating protein GAP but nevertheless has transforming properties</article-title>
            <source>J Biol Chem</source>
            <volume>266</volume>
            <fpage>17700</fpage>
            <lpage>17706</lpage>
            <year>1991</year>
            <pub-id pub-id-type="pmid">1894650</pub-id>
          </element-citation>
        </ref>
        <ref id="R28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lin</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Cerione</surname>
                <given-names>RA</given-names>
              </name>
              <name name-style="western">
                <surname>Manor</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation</article-title>
            <source>J Biol Chem</source>
            <volume>274</volume>
            <fpage>23633</fpage>
            <lpage>23641</lpage>
            <year>1999</year>
            <pub-id pub-id-type="pmid">10438546</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.274.33.23633</pub-id>
          </element-citation>
        </ref>
        <ref id="R29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ridley</surname>
                <given-names>AJ</given-names>
              </name>
              <name name-style="western">
                <surname>Paterson</surname>
                <given-names>HF</given-names>
              </name>
              <name name-style="western">
                <surname>Johnston</surname>
                <given-names>CL</given-names>
              </name>
              <name name-style="western">
                <surname>Diekmann</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Hall</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The small GTP-binding protein rac regulates growth factor-induced membrane ruffling</article-title>
            <source>Cell</source>
            <volume>70</volume>
            <fpage>401</fpage>
            <lpage>410</lpage>
            <year>1992</year>
            <pub-id pub-id-type="pmid">1643658</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(92)90164-8</pub-id>
          </element-citation>
        </ref>
        <ref id="R30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Broekaert</surname>
                <given-names>SM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genetic and morphologic features for melanoma classification</article-title>
            <source>Pigment Cell Melanoma Res</source>
            <volume>23</volume>
            <fpage>763</fpage>
            <lpage>770</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20874733</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-148X.2010.00778.x</pub-id>
            <pub-id pub-id-type="pmcid">PMC3107973</pub-id>
          </element-citation>
        </ref>
        <ref id="R31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Viros</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Improving melanoma classification by integrating genetic and morphologic features</article-title>
            <source>PLoS Med</source>
            <volume>5</volume>
            <fpage>e120</fpage>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18532874</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0050120</pub-id>
            <pub-id pub-id-type="pmcid">PMC2408611</pub-id>
          </element-citation>
        </ref>
        <ref id="R32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Crespo-Hernández</surname>
                <given-names>CE</given-names>
              </name>
              <name name-style="western">
                <surname>Cohen</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Kohler</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Base stacking controls excited-state dynamics in A.T DNA</article-title>
            <source>Nature</source>
            <volume>436</volume>
            <fpage>1141</fpage>
            <lpage>1144</lpage>
            <year>2005</year>
            <pub-id pub-id-type="pmid">16121177</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature03933</pub-id>
          </element-citation>
        </ref>
        <ref id="R33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ziegler</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers</article-title>
            <source>Proc Natl Acad Sci USA</source>
            <volume>90</volume>
            <fpage>4216</fpage>
            <lpage>4220</lpage>
            <year>1993</year>
            <pub-id pub-id-type="pmid">8483937</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.90.9.4216</pub-id>
            <pub-id pub-id-type="pmcid">PMC46477</pub-id>
          </element-citation>
        </ref>
        <ref id="R34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Turajlic</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Whole genome sequencing of matched primary and metastatic acral melanomas</article-title>
            <source>Genome Res</source>
            <volume>22</volume>
            <fpage>196</fpage>
            <lpage>207</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22183965</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.125591.111</pub-id>
            <pub-id pub-id-type="pmcid">PMC3266028</pub-id>
          </element-citation>
        </ref>
        <ref id="R35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Furney</surname>
                <given-names>SJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic characterisation of acral melanoma cell lines</article-title>
            <source>Pigment Cell Melanoma Res</source>
            <volume>25</volume>
            <fpage>488</fpage>
            <lpage>492</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22578220</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-148X.2012.01016.x</pub-id>
          </element-citation>
        </ref>
        <ref id="R36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inactivating mutations of the chromatin remodeling gene <italic toggle="yes">ARID2</italic> in hepatocellular carcinoma</article-title>
            <source>Nat Genet</source>
            <volume>43</volume>
            <fpage>828</fpage>
            <lpage>829</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21822264</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.903</pub-id>
            <pub-id pub-id-type="pmcid">PMC3163746</pub-id>
          </element-citation>
        </ref>
        <ref id="R37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Flavell</surname>
                <given-names>JR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Down-regulation of the TGF-β target gene, <italic toggle="yes">PTPRK</italic>, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells</article-title>
            <source>Blood</source>
            <volume>111</volume>
            <fpage>292</fpage>
            <lpage>301</lpage>
            <year>2008</year>
            <pub-id pub-id-type="pmid">17720884</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2006-11-059881</pub-id>
          </element-citation>
        </ref>
        <ref id="R38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pollock</surname>
                <given-names>PM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>High frequency of <italic toggle="yes">BRAF</italic> mutations in nevi</article-title>
            <source>Nat Genet</source>
            <volume>33</volume>
            <fpage>19</fpage>
            <lpage>20</lpage>
            <year>2003</year>
            <pub-id pub-id-type="pmid">12447372</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng1054</pub-id>
          </element-citation>
        </ref>
        <ref id="R39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bauer</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Curtin</surname>
                <given-names>JA</given-names>
              </name>
              <name name-style="western">
                <surname>Pinkel</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Bastian</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Congenital melanocytic nevi frequently harbor <italic toggle="yes">NRAS</italic> mutations but no <italic toggle="yes">BRAF</italic> mutations</article-title>
            <source>J Invest Dermatol</source>
            <volume>127</volume>
            <fpage>179</fpage>
            <lpage>182</lpage>
            <year>2007</year>
            <pub-id pub-id-type="pmid">16888631</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.jid.5700490</pub-id>
          </element-citation>
        </ref>
        <ref id="R40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vredeveld</surname>
                <given-names>LC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis</article-title>
            <source>Genes Dev</source>
            <volume>26</volume>
            <fpage>1055</fpage>
            <lpage>1069</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22549727</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.187252.112</pub-id>
            <pub-id pub-id-type="pmcid">PMC3360561</pub-id>
          </element-citation>
        </ref>
        <ref id="R41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Nogueira</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis</article-title>
            <source>Oncogene</source>
            <volume>29</volume>
            <fpage>6222</fpage>
            <lpage>6232</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20711233</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2010.349</pub-id>
            <pub-id pub-id-type="pmcid">PMC2989338</pub-id>
          </element-citation>
        </ref>
        <ref id="R42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zeng</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Bastos</surname>
                <given-names>RN</given-names>
              </name>
              <name name-style="western">
                <surname>Barr</surname>
                <given-names>FA</given-names>
              </name>
              <name name-style="western">
                <surname>Gruneberg</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Protein phosphatase 6 regulates mitotic spindle formation by controlling the T-loop phosphorylation state of Aurora A bound to its activator TPX2</article-title>
            <source>J Cell Biol</source>
            <volume>191</volume>
            <fpage>1315</fpage>
            <lpage>1332</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">21187329</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201008106</pub-id>
            <pub-id pub-id-type="pmcid">PMC3010072</pub-id>
          </element-citation>
        </ref>
        <ref id="R43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Barr</surname>
                <given-names>FA</given-names>
              </name>
              <name name-style="western">
                <surname>Elliott</surname>
                <given-names>PR</given-names>
              </name>
              <name name-style="western">
                <surname>Gruneberg</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Protein phosphatases and the regulation of mitosis</article-title>
            <source>J Cell Sci</source>
            <volume>124</volume>
            <fpage>2323</fpage>
            <lpage>2334</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21709074</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.087106</pub-id>
          </element-citation>
        </ref>
        <ref id="R44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Douglas</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates γ-H2AX</article-title>
            <source>Mol Cell Biol</source>
            <volume>30</volume>
            <fpage>1368</fpage>
            <lpage>1381</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20065038</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MCB.00741-09</pub-id>
            <pub-id pub-id-type="pmcid">PMC2832507</pub-id>
          </element-citation>
        </ref>
        <ref id="R45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Manfredi</surname>
                <given-names>MG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel <italic toggle="yes">in vivo</italic> pharmacodynamic assays</article-title>
            <source>Clin Cancer Res</source>
            <volume>17</volume>
            <fpage>7614</fpage>
            <lpage>7624</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">22016509</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-11-1536</pub-id>
          </element-citation>
        </ref>
        <ref id="R46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sehdev</surname>
                <given-names>V</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The Aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells</article-title>
            <source>Mol Cancer Ther</source>
            <volume>11</volume>
            <fpage>763</fpage>
            <lpage>774</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22302096</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-11-0623</pub-id>
            <pub-id pub-id-type="pmcid">PMC3297687</pub-id>
          </element-citation>
        </ref>
        <ref id="R47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jensen</surname>
                <given-names>JS</given-names>
              </name>
              <name name-style="western">
                <surname>Omarsdottir</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Thorsteinsdottir</surname>
                <given-names>JB</given-names>
              </name>
              <name name-style="western">
                <surname>Ogmundsdottir</surname>
                <given-names>HM</given-names>
              </name>
              <name name-style="western">
                <surname>Olafsdottir</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Synergistic cytotoxic effect of the microtubule inhibitor marchantin a from marchantia polymorpha and the Aurora kinase inhibitor MLN8237 on breast cancer cells <italic toggle="yes">in vitro</italic></article-title>
            <source>Planta Med</source>
            <volume>78</volume>
            <fpage>448</fpage>
            <lpage>454</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22331811</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0031-1298230</pub-id>
          </element-citation>
        </ref>
        <ref id="R48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Macarulla</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics</article-title>
            <source>Mol Cancer Ther</source>
            <volume>9</volume>
            <fpage>2844</fpage>
            <lpage>2852</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20724522</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-10-0299</pub-id>
          </element-citation>
        </ref>
        <ref id="R49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chadee</surname>
                <given-names>DN</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein</article-title>
            <source>Proc Natl Acad Sci USA</source>
            <volume>103</volume>
            <fpage>4463</fpage>
            <lpage>4468</lpage>
            <year>2006</year>
            <pub-id pub-id-type="pmid">16537381</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0510651103</pub-id>
            <pub-id pub-id-type="pmcid">PMC1450194</pub-id>
          </element-citation>
        </ref>
        <ref id="R50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Castets</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>DCC constrains tumour progression via its dependence receptor activity</article-title>
            <source>Nature</source>
            <volume>482</volume>
            <fpage>534</fpage>
            <lpage>537</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22158121</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10708</pub-id>
          </element-citation>
        </ref>
        <ref id="R51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Krimpenfort</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours</article-title>
            <source>Nature</source>
            <volume>482</volume>
            <fpage>538</fpage>
            <lpage>541</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22358843</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10790</pub-id>
          </element-citation>
        </ref>
        <ref id="R52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Stransky</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The mutational landscape of head and neck squamous cell carcinoma</article-title>
            <source>Science</source>
            <volume>333</volume>
            <fpage>1157</fpage>
            <lpage>1160</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21798893</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1208130</pub-id>
            <pub-id pub-id-type="pmcid">PMC3415217</pub-id>
          </element-citation>
        </ref>
        <ref id="R53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Barretina</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>
            <source>Nature</source>
            <volume>483</volume>
            <fpage>603</fpage>
            <lpage>607</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22460905</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11003</pub-id>
            <pub-id pub-id-type="pmcid">PMC3320027</pub-id>
          </element-citation>
        </ref>
        <ref id="R54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Li</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Rac1 drives melanoblast organization during mouse development by orchestrating pseudopod-driven motility and cell-cycle progression</article-title>
            <source>Dev Cell</source>
            <volume>21</volume>
            <fpage>722</fpage>
            <lpage>734</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21924960</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2011.07.008</pub-id>
            <pub-id pub-id-type="pmcid">PMC3464460</pub-id>
          </element-citation>
        </ref>
        <ref id="R55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lindsay</surname>
                <given-names>CR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>P-Rex1 is required for efficient melanoblast migration and melanoma metastasis</article-title>
            <source>Nat Commun</source>
            <volume>2</volume>
            <fpage>555</fpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">22109529</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms1560</pub-id>
            <pub-id pub-id-type="pmcid">PMC3400057</pub-id>
          </element-citation>
        </ref>
        <ref id="R56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Xing</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins</article-title>
            <source>Cell</source>
            <volume>127</volume>
            <fpage>341</fpage>
            <lpage>353</lpage>
            <year>2006</year>
            <pub-id pub-id-type="pmid">17055435</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2006.09.025</pub-id>
          </element-citation>
        </ref>
        <ref id="R57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pai</surname>
                <given-names>EF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis</article-title>
            <source>EMBO J</source>
            <volume>9</volume>
            <fpage>2351</fpage>
            <lpage>2359</lpage>
            <year>1990</year>
            <pub-id pub-id-type="pmid">2196171</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1460-2075.1990.tb07409.x</pub-id>
            <pub-id pub-id-type="pmcid">PMC552258</pub-id>
          </element-citation>
        </ref>
        <ref id="R58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Potterton</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Developments in the CCP4 molecular-graphics project</article-title>
            <source>Acta Crystallogr D Biol Crystallogr</source>
            <volume>60</volume>
            <fpage>2288</fpage>
            <lpage>2294</lpage>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15572783</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1107/S0907444904023716</pub-id>
          </element-citation>
        </ref>
        <ref id="R59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Halaban</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells</article-title>
            <source>Pigment Cell Melanoma Res</source>
            <volume>23</volume>
            <fpage>190</fpage>
            <lpage>200</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20149136</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-148X.2010.00685.x</pub-id>
            <pub-id pub-id-type="pmcid">PMC2848976</pub-id>
          </element-citation>
        </ref>
        <ref id="R60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Donnelly</surname>
                <given-names>MP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The distribution and most recent common ancestor of the 17q21 inversion in humans</article-title>
            <source>Am J Hum Genet</source>
            <volume>86</volume>
            <fpage>161</fpage>
            <lpage>171</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20116045</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2010.01.007</pub-id>
            <pub-id pub-id-type="pmcid">PMC2820164</pub-id>
          </element-citation>
        </ref>
        <ref id="R61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tworkoski</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phosphoproteomic screen identifies potential therapeutic targets in melanoma</article-title>
            <source>Mol Cancer Res</source>
            <volume>9</volume>
            <fpage>801</fpage>
            <lpage>812</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21521745</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1541-7786.MCR-10-0512</pub-id>
            <pub-id pub-id-type="pmcid">PMC3117976</pub-id>
          </element-citation>
        </ref>
        <ref id="R62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kong</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Btrim: A fast, lightweight adapter and quality trimming program for next-generation sequencing technologies</article-title>
            <source>Genomics</source>
            <volume>98</volume>
            <fpage>152</fpage>
            <lpage>153</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21651976</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygeno.2011.05.009</pub-id>
          </element-citation>
        </ref>
        <ref id="R63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Durbin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>
            <source>Bioinformatics</source>
            <volume>25</volume>
            <fpage>1754</fpage>
            <lpage>1760</lpage>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19451168</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp324</pub-id>
            <pub-id pub-id-type="pmcid">PMC2705234</pub-id>
          </element-citation>
        </ref>
        <ref id="R64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The Sequence Alignment/Map format and SAMtools</article-title>
            <source>Bioinformatics</source>
            <volume>25</volume>
            <fpage>2078</fpage>
            <lpage>2079</lpage>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19505943</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp352</pub-id>
            <pub-id pub-id-type="pmcid">PMC2723002</pub-id>
          </element-citation>
        </ref>
        <ref id="R65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Garla</surname>
                <given-names>V</given-names>
              </name>
              <name name-style="western">
                <surname>Kong</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Szpakowski</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Krauthammer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>MU2A—reconciling the genome and transcriptome to determine the effects of base substitutions</article-title>
            <source>Bioinformatics</source>
            <volume>27</volume>
            <fpage>416</fpage>
            <lpage>418</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21149339</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btq658</pub-id>
            <pub-id pub-id-type="pmcid">PMC3031033</pub-id>
          </element-citation>
        </ref>
        <ref id="R66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sathirapongsasuti</surname>
                <given-names>JF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV</article-title>
            <source>Bioinformatics</source>
            <volume>27</volume>
            <fpage>2648</fpage>
            <lpage>2654</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21828086</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btr462</pub-id>
            <pub-id pub-id-type="pmcid">PMC3179661</pub-id>
          </element-citation>
        </ref>
        <ref id="R67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Thorvaldsdóttir</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Robinson</surname>
                <given-names>JT</given-names>
              </name>
              <name name-style="western">
                <surname>Mesirov</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration</article-title>
            <source>Brief Bioinform</source>
            <comment>published online</comment>
            <pub-id pub-id-type="doi">10.1093/bib/bbs017</pub-id>
            <day>19</day>
            <month>4</month>
            <year>2012</year>
            <pub-id pub-id-type="pmcid">PMC3603213</pub-id>
            <pub-id pub-id-type="pmid">22517427</pub-id>
          </element-citation>
        </ref>
        <ref id="R68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Koboldt</surname>
                <given-names>DC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing</article-title>
            <source>Genome Res</source>
            <volume>22</volume>
            <fpage>568</fpage>
            <lpage>576</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22300766</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.129684.111</pub-id>
            <pub-id pub-id-type="pmcid">PMC3290792</pub-id>
          </element-citation>
        </ref>
        <ref id="R69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data</article-title>
            <source>Bioinformatics</source>
            <volume>26</volume>
            <fpage>464</fpage>
            <lpage>469</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20031968</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp708</pub-id>
            <pub-id pub-id-type="pmcid">PMC2852218</pub-id>
          </element-citation>
        </ref>
        <ref id="R70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Wu</surname>
                <given-names>YI</given-names>
              </name>
              <name name-style="western">
                <surname>Hahn</surname>
                <given-names>KM</given-names>
              </name>
              <name name-style="western">
                <surname>Montell</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Light-mediated activation reveals a key role for Rac in collective guidance of cell movement <italic toggle="yes">in vivo</italic></article-title>
            <source>Nat Cell Biol</source>
            <volume>12</volume>
            <fpage>591</fpage>
            <lpage>597</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20473296</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncb2061</pub-id>
            <pub-id pub-id-type="pmcid">PMC2929827</pub-id>
          </element-citation>
        </ref>
        <ref id="R71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wu</surname>
                <given-names>YI</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A genetically encoded photoactivatable Rac controls the motility of living cells</article-title>
            <source>Nature</source>
            <volume>461</volume>
            <fpage>104</fpage>
            <lpage>108</lpage>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19693014</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature08241</pub-id>
            <pub-id pub-id-type="pmcid">PMC2766670</pub-id>
          </element-citation>
        </ref>
        <ref id="R72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Machacek</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Coordination of Rho GTPase activities during cell protrusion</article-title>
            <source>Nature</source>
            <volume>461</volume>
            <fpage>99</fpage>
            <lpage>103</lpage>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19693013</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature08242</pub-id>
            <pub-id pub-id-type="pmcid">PMC2885353</pub-id>
          </element-citation>
        </ref>
        <ref id="R73">
          <label>73</label>
          <element-citation publication-type="book">
            <person-group person-group-type="editor">
              <name name-style="western">
                <surname>Otwinowski</surname>
                <given-names>Z</given-names>
              </name>
              <name name-style="western">
                <surname>Minor</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Processing of X-ray diffraction data collected in oscillation mode</article-title>
            <source>Methods in Enzymology</source>
            <volume>276</volume>
            <comment>Ch. 20</comment>
            <fpage>307</fpage>
            <lpage>326</lpage>
            <publisher-name>Academic Press</publisher-name>
            <publisher-loc>New York</publisher-loc>
            <year>1997</year>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0076-6879(97)76066-X</pub-id>
            <pub-id pub-id-type="pmid">27754618</pub-id>
          </element-citation>
        </ref>
        <ref id="R74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>McCoy</surname>
                <given-names>AJ</given-names>
              </name>
              <name name-style="western">
                <surname>Grosse-Kunstleve</surname>
                <given-names>RW</given-names>
              </name>
              <name name-style="western">
                <surname>Storoni</surname>
                <given-names>LC</given-names>
              </name>
              <name name-style="western">
                <surname>Read</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Likelihood-enhanced fast translation functions</article-title>
            <source>Acta Crystallogr D Biol Crystallogr</source>
            <volume>61</volume>
            <fpage>458</fpage>
            <lpage>464</lpage>
            <year>2005</year>
            <pub-id pub-id-type="pmid">15805601</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1107/S0907444905001617</pub-id>
          </element-citation>
        </ref>
        <ref id="R75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hirshberg</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Stockley</surname>
                <given-names>RW</given-names>
              </name>
              <name name-style="western">
                <surname>Dodson</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Webb</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>The crystal structure of human rac1, a member of the rho-family complexed with a GTP analogue</article-title>
            <source>Nat Struct Biol</source>
            <volume>4</volume>
            <fpage>147</fpage>
            <lpage>152</lpage>
            <year>1997</year>
            <pub-id pub-id-type="pmid">9033596</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nsb0297-147</pub-id>
          </element-citation>
        </ref>
        <ref id="R76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Perrakis</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Harkiolaki</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Wilson</surname>
                <given-names>KS</given-names>
              </name>
              <name name-style="western">
                <surname>Lamzin</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>ARP/wARP and molecular replacement</article-title>
            <source>Acta Crystallogr D Biol Crystallogr</source>
            <volume>57</volume>
            <fpage>1445</fpage>
            <lpage>1450</lpage>
            <year>2001</year>
            <pub-id pub-id-type="pmid">11567158</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1107/s0907444901014007</pub-id>
          </element-citation>
        </ref>
        <ref id="R77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Murshudov</surname>
                <given-names>GN</given-names>
              </name>
              <name name-style="western">
                <surname>Vagin</surname>
                <given-names>AA</given-names>
              </name>
              <name name-style="western">
                <surname>Dodson</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title>
            <source>Acta Crystallogr D Biol Crystallogr</source>
            <volume>53</volume>
            <fpage>240</fpage>
            <lpage>255</lpage>
            <year>1997</year>
            <pub-id pub-id-type="pmid">15299926</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1107/S0907444996012255</pub-id>
          </element-citation>
        </ref>
        <ref id="R78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Emsley</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Cowtan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Coot: model-building tools for molecular graphics</article-title>
            <source>Acta Crystallogr D Biol Crystallogr</source>
            <volume>60</volume>
            <fpage>2126</fpage>
            <lpage>2132</lpage>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15572765</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1107/S0907444904019158</pub-id>
          </element-citation>
        </ref>
        <ref id="R79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chen</surname>
                <given-names>VB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title>
            <source>Acta Crystallogr D Biol Crystallogr</source>
            <volume>66</volume>
            <fpage>12</fpage>
            <lpage>21</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20057044</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1107/S0907444909042073</pub-id>
            <pub-id pub-id-type="pmcid">PMC2803126</pub-id>
          </element-citation>
        </ref>
        <ref id="R80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name name-style="western">
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The role of Mg<sup>2+</sup> cofactor in the guanine nucleotide exchange and GTP hydrolysis reactions of Rho family GTP-binding proteins</article-title>
            <source>J Biol Chem</source>
            <volume>275</volume>
            <fpage>25299</fpage>
            <lpage>25307</lpage>
            <year>2000</year>
            <pub-id pub-id-type="pmid">10843989</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M001027200</pub-id>
          </element-citation>
        </ref>
        <ref id="R81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Nagata</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The MAP kinase kinase kinase MLK2 co-localizes with activated JNK along microtubules and associates with kinesin superfamily motor KIF3</article-title>
            <source>EMBO J</source>
            <volume>17</volume>
            <fpage>149</fpage>
            <lpage>158</lpage>
            <year>1998</year>
            <pub-id pub-id-type="pmid">9427749</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/emboj/17.1.149</pub-id>
            <pub-id pub-id-type="pmcid">PMC1170366</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
    <floats-group>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Mutation spectrum in melanoma samples. (<bold>a</bold>) Numbers of somatic nonsynonymous mutations across 99 matched melanoma samples. The tumors are represented as originating from sun-exposed skin (dark orange bars) or sun-shielded skin (acral (A), mucosal (M) or uveal (U), shown in different shades of light orange) or are melanomas of unknown origin (gray bars). Melanomas from primary compared to metastasis, the age of the patients and <italic toggle="yes">BRAF</italic> and <italic toggle="yes">RAS</italic> mutation status are also indicated. Mut, mutated; WT, wild type. <italic toggle="yes">NRAS</italic> is the most common <italic toggle="yes">RAS</italic> mutant gene, except for one acral melanoma that harbored the <italic toggle="yes">HRAS</italic> mutation resulting in p.Gln61His (brown). All <italic toggle="yes">BRAF</italic> and <italic toggle="yes">RAS</italic> mutations were validated by Sanger sequencing. The inset shows an expanded scale of the number of mutations in tumors at the lower range. (<bold>b</bold>) The number of mutations in relation to the age of the patients. (<bold>c</bold>) Spectrum of somatic variants in exomes of sun-exposed and sun-shielded (acral, mucosal and uveal) melanomas. There is an excess of C&gt;T transitions in dipyrimidines in sun-exposed melanomas, which is an indication of UV exposure and DNA damage. The <italic toggle="yes">n</italic> values indicate the number of mutations; because any base has a 25% chance of being flanked by a purine on both sides, the frequency at which a mutated base is part of a dipyrimidine by chance is exactly threefold the frequency for nondipyrimidines. (<bold>d</bold>) Consensus sequence for positions with recurrent (at least three) and nonrecurrent mutations, as indicated. The recurrent mutations are located at a known hotspot sequence motif for cyclobutane pyrimidine dimer formation. The motif represents the actual prevalence of each sequence context without normalizing for the mammalian under-representation of CG dinucleotides.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms390374f1.jpg"/>
      </fig>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Schematic representation of PPP6C alterations. (<bold>a</bold>) Map of PPP6C functional domains and the sites of amino acid substitutions. The horizontal bar shows the 342 amino acids of PPP6C (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="NP_001116827.1">NP_001116827.1</ext-link>), the light gray bar shows the serine/threonine phosphatase domain, and the red peaks indicate the active site, the metal-binding sites and the heterodimer interface downloaded from NCBI. The red circles indicate the 11 mutations we discovered in the complete melanoma cohort and validated as somatic by Sanger sequencing. Recurrent mutations are indicated by multiple circles. (<bold>b</bold>) Mutant residues in PPP6C mapped onto the crystal structure of the phosphatase domain of PP2A (Protein Data Bank (PDB) 2IE4)<sup><xref rid="R56" ref-type="bibr">56</xref></sup>. All but one of the amino acids found to be mutated are conserved between PPP6C and PP2A. The PP2A structure is in complex with tumor-inducing okadaic acid, shown as solid spheres, which binds to the catalytic cleft. Mutations discovered in melanoma are shown in red. There is a clear preference for melanoma mutations to occur in the catalytic cleft of PPP6C.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms390374f2.jpg"/>
      </fig>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Distribution of SCNAs and genes with high mutation loads in melanomas. (<bold>a</bold>) A plot showing copy number aberrations and high somatic nonsynonymous mutation load. Red and brown indicate copy gain and loss, respectively, as related to chromosome band (right) and focal gene in the region (left). Mutations are marked in blue, and mutations occurring at LOH are shown in purple. At the bottom, the melanoma subtypes described in <xref rid="F1" ref-type="fig">Figure 1a</xref> are indicated. (<bold>b</bold>) A plot of genes with a high load of somatic nonsense mutations. The bars indicate point mutations (orange), indels (pink) and splice-site variants (purple) that lead to frame shifts and early chain termination.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms390374f3.jpg"/>
      </fig>
      <fig id="F4" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Crystal structure of RAC1<sup>P29S</sup>. (<bold>a</bold>) Overall schematic of RAC1<sup>P29S</sup> showing the P-loop (pink), switch I (light green), switch II (purple), Mg<sup>2+</sup> (cyan) and the slowly hydrolyzing GTP analog, GMP-PNP (stick format). The red sphere indicates the location of p.Pro29Ser. The dashed box indicates the regions shown in <bold>b</bold>–<bold>e</bold>. (<bold>b</bold>) Close-up view showing close contacts of ribose hydroxyls with the switch I region in RAC1<sup>P29S</sup>. (<bold>c</bold>) RAC1<sup>WT</sup> bound to GMP-PNP. (<bold>d</bold>) HRAS in complex with GMP-PNP (PDB 5P21)<sup><xref rid="R57" ref-type="bibr">57</xref></sup>. Direct hydrogen bonding between the switch I backbone and ribose are commonly observed in activated HRAS but are less frequently observed in Rho family GTPases, including RAC1. A RAS-like hydrogen bonding pattern is observed in activated RAC1<sup>P29S</sup> (dashed red lines). (<bold>e</bold>) Superposition of the switch I region and GMP-PNP. RAC1<sup>P29S</sup> is shown in light green, RAC1<sup>WT</sup> is shown in gray, and HRAS is shown in light blue. The red sphere indicates the location of p.Pro29Ser. The residues discussed in the text are labeled. The figure was made using CCP4mg<sup><xref rid="R58" ref-type="bibr">58</xref></sup>.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms390374f4.jpg"/>
      </fig>
      <fig id="F5" orientation="portrait" position="float">
        <label>Figure 5</label>
        <caption>
          <p><italic toggle="yes">In vitro</italic> RAC1<sup>P29S</sup> binding to downstream effectors. (<bold>a</bold>) PAK1 pulldown assay showing that recombinant histidine-tagged RAC1<sup>P29S</sup> (His-RAC1<sup>P29S</sup>) has higher binding to its effector PAK1 compared to His-RAC1<sup>WT</sup> for samples that include GTP and GTPγS. NC, PAK1-PBD beads alone as a negative control. The His-RAC1<sup>WT</sup> and His-RAC<sup>P29S</sup> lanes show unbound wild-type and mutant protein, as indicated. The multiple bands in all lanes are RAC1; all bands are observed when RAC1 crystals are run on SDS-PAGE. (<bold>b</bold>) RAC1 pulldown assay showing that recombinant His-GST-RAC1<sup>P29S</sup> has higher binding to endogenous MLK3 expressed in melanoma cells compared to His-GST-RAC1<sup>WT</sup> in all reaction samples. The immobilized recombinant RAC1 proteins were incubated with cell lysates from two independent melanomas (YULAC that is RAC1<sup>WT</sup> and BRAF<sup>V600K</sup> and YUHEF that is RAC1<sup>P29S</sup> and BRAF<sup>WT</sup>). The figure shows western blot of bound proteins with antibodies to MLK3. As negative controls, we used lysates incubated with GST-bound beads or recombinant RAC1 proteins that were not incubated with cell extracts. The western blot analysis also shows the expression of the relevant proteins in whole-cell lysate (WCL). The reaction mixtures were likely to contain nucleotides contributed by the cell lysates in addition to those added <italic toggle="yes">in vitro</italic>, as indicated. (<bold>c</bold>) PAK1 pulldown assay comparing the binding activity of RAC1<sup>WT</sup>, RAC1<sup>P29S</sup> and RAC1<sup>F28L</sup> proteins. The numbers under each lane indicate the band density as determined by scanning the membranes with ImageJ.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms390374f5.jpg"/>
      </fig>
      <fig id="F6" orientation="portrait" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Cellular function of RAC1<sup>P29S</sup> compared to RAC1<sup>WT</sup>. (<bold>a</bold>) Western blot analysis of RAC1 in mouse melanocytes infected with wild-type (WT) or mutant RAC<sup>P29S</sup> retroviral expression vectors compared to nontransfected cells (parental). Actin indicates protein loading in each lane. (<bold>b</bold>) RAC1<sup>P29S</sup> enhances melanocyte proliferation. The proliferation of melanocytes transiently expressing RAC1<sup>WT</sup> (green) or RAC1<sup>P29S</sup> (red) compared to noninfected parental cells (blue). Error bars indicate standard errors. (<bold>c</bold>) RAC1<sup>P29S</sup> enhances cell migration. The graphs show the rate of migration of parental, RAC1<sup>WT</sup>- and RAC1<sup>P29S</sup>-expressing melanocytes at daily intervals. (<bold>d</bold>) RAC1<sup>P29S</sup> enhances ERK activation. Western blots of lysates from mouse melanocytes expressing RAC1<sup>WT</sup> or RAC1<sup>P29S</sup> probed with RAC1, pERK, ERK and actin antibodies, as indicated on the side of the gel. (<bold>e</bold>) Localization of GFP-tagged RAC1<sup>WT</sup> (GFP-RAC1<sup>WT</sup>) and GFP-RAC1<sup>P29S</sup> in COS-7 cells. COS-7 cells transiently expressing GFP-RAC1<sup>WT</sup> (i, ii) or GFP-RAC1<sup>P29S</sup> (iii, iv) were fixed with paraformaldehyde and imaged with a spinning-disk confocal-based inverted Olympus microscope. Insets (yellow boxes) illustrate the localization of RAC1<sup>P29S</sup>, but not RAC1<sup>WT</sup>, in membrane ruffles (compare i and ii to the yellow arrows in iii and iv, respectively). pERK, phosphorylated ERK. Scale bars, 10 μm.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms390374f6.jpg"/>
      </fig>
      <table-wrap id="T1" position="float" orientation="portrait">
        <label>Table 1</label>
        <caption>
          <p>Expressed genes with significant overall mutation burden in sun-exposed melanoma</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Gene</th>
              <th valign="bottom" align="right" rowspan="1" colspan="1">Length (bp)</th>
              <th valign="bottom" align="right" rowspan="1" colspan="1">Number of samples with somatic SNVs</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">
                <italic toggle="yes">P</italic>
              </th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">
                <italic toggle="yes">P</italic>
                <sub>BH</sub>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">BRAF</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">2,290</td>
              <td align="right" valign="top" rowspan="1" colspan="1">28</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6.65 × 10<sup>−47</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">3.48 × 10<sup>−43</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">NRAS</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">565</td>
              <td align="right" valign="top" rowspan="1" colspan="1">13</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.27 × 10<sup>−21</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">4.99 × 10<sup>−18</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">DCC</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">4,171</td>
              <td align="right" valign="top" rowspan="1" colspan="1">21</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2.02 × 10<sup>−12</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">6.34 × 10<sup>−9</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">TNC</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">5,819</td>
              <td align="right" valign="top" rowspan="1" colspan="1">11</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.98 × 10<sup>−9</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">3.88 × 10<sup>−6</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">TP53</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">1,112</td>
              <td align="right" valign="top" rowspan="1" colspan="1">9</td>
              <td align="left" valign="top" rowspan="1" colspan="1">5.04 × 10<sup>−8</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">8.80 × 10<sup>−5</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">PTPRK</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">4,118</td>
              <td align="right" valign="top" rowspan="1" colspan="1">12</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.37 × 10<sup>−7</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">2.16 × 10<sup>−4</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">PPP6C</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">928</td>
              <td align="right" valign="top" rowspan="1" colspan="1">8</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.61 × 10<sup>−7</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">2.17 × 10<sup>−4</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">TLR4</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">1,802</td>
              <td align="right" valign="top" rowspan="1" colspan="1">8</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.65 × 10<sup>−7</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">2.17 × 10<sup>−4</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">CD163L1</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">3,877</td>
              <td align="right" valign="top" rowspan="1" colspan="1">15</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2.85 × 10<sup>−7</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">3.20 × 10<sup>−4</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">GRM3</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">2,124</td>
              <td align="right" valign="top" rowspan="1" colspan="1">12</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6.43 × 10<sup>−7</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">5.95 × 10<sup>−4</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">NPAP1</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">2,248</td>
              <td align="right" valign="top" rowspan="1" colspan="1">13</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.37 × 10<sup>−5</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">7.44 × 10<sup>−3</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">SLC15A2</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">2,186</td>
              <td align="right" valign="top" rowspan="1" colspan="1">11</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.67 × 10<sup>−5</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">8.19 × 10<sup>−3</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">RAC1</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">607</td>
              <td align="right" valign="top" rowspan="1" colspan="1">6</td>
              <td align="left" valign="top" rowspan="1" colspan="1">3.12 × 10<sup>−5</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.26 × 10<sup>−2</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">MAGEC1</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">2,245</td>
              <td align="right" valign="top" rowspan="1" colspan="1">8</td>
              <td align="left" valign="top" rowspan="1" colspan="1">4.29 × 10<sup>−5</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.69 × 10<sup>−2</sup></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <italic toggle="yes">JAKMIP2</italic>
              </td>
              <td align="right" valign="top" rowspan="1" colspan="1">2,356</td>
              <td align="right" valign="top" rowspan="1" colspan="1">12</td>
              <td align="left" valign="top" rowspan="1" colspan="1">9.00 × 10<sup>−5</sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">2.89 × 10<sup>−2</sup></td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN1">
            <p>The numbers are based on samples of melanomas with matched germline DNA (<italic toggle="yes">n</italic> = 61). <italic toggle="yes">P</italic> indicates the uncorrected <italic toggle="yes">P</italic> value; <italic toggle="yes">P</italic><sub>BH</sub> indicates the Benjamini-Hochberg–corrected <italic toggle="yes">P</italic> value. The length in bp corresponds to the number of bases in the exome capture region. The <italic toggle="yes">P</italic> values were derived from testing the observed somatic SNVs against an estimated tumor background mutation frequency.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="T2" position="float" orientation="portrait">
        <label>Table 2</label>
        <caption>
          <p>Statistical analysis of <italic toggle="yes">RAC1</italic><sup>P29S</sup> in the Yale tumor cohort</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Category</th>
              <th valign="bottom" align="center" rowspan="1" colspan="1">Percentage with RAC1<sup>P29S</sup></th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">
                <italic toggle="yes">P</italic>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Male</td>
              <td align="center" valign="top" rowspan="1" colspan="1">12.8</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.01</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Female</td>
              <td align="center" valign="top" rowspan="1" colspan="1">2.4</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Primary</td>
              <td align="center" valign="top" rowspan="1" colspan="1">9.2</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.92</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Metastatic</td>
              <td align="center" valign="top" rowspan="1" colspan="1">8.6</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">BRAF</italic> mutant</td>
              <td align="center" valign="top" rowspan="1" colspan="1">7.4</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.76</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">BRAF</italic> WT</td>
              <td align="center" valign="top" rowspan="1" colspan="1">9.5</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">NRAS</italic> mutant</td>
              <td align="center" valign="top" rowspan="1" colspan="1">6.3</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.77</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">NRAS</italic> WT</td>
              <td align="center" valign="top" rowspan="1" colspan="1">9.5</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">NRAS</italic> or <italic toggle="yes">BRAF</italic> mutant</td>
              <td align="center" valign="top" rowspan="1" colspan="1">6.2</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.17</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">NRAS</italic> and <italic toggle="yes">BRAF</italic> WT</td>
              <td align="center" valign="top" rowspan="1" colspan="1">12.5</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">DCC</italic> mutant</td>
              <td align="center" valign="top" rowspan="1" colspan="1">28.6</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.001</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">DCC</italic> WT</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">MAPK</italic> mutant</td>
              <td align="center" valign="top" rowspan="1" colspan="1">26.3</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.009</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">MAPK</italic> WT</td>
              <td align="center" valign="top" rowspan="1" colspan="1">2.4</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">C15orf2</italic> mutant</td>
              <td align="center" valign="top" rowspan="1" colspan="1">30.7</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.015</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">C15orf2</italic> WT</td>
              <td align="center" valign="top" rowspan="1" colspan="1">4</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">ZNF560</italic> mutant</td>
              <td align="center" valign="top" rowspan="1" colspan="1">37.5</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">ZNF560</italic> WT</td>
              <td align="center" valign="top" rowspan="1" colspan="1">5.7</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CD163L1</italic> mutant</td>
              <td align="center" valign="top" rowspan="1" colspan="1">26.7</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CD163L1</italic> WT</td>
              <td align="center" valign="top" rowspan="1" colspan="1">4.3</td>
              <td align="left" valign="top" rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN2">
            <p>The male and female, primary and metastatic and <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic> status numbers are based on available annotations for sun-exposed melanomas in the Yale cohort (<italic toggle="yes">n</italic> = 217). The other gene frequency numbers are based on a subset of 61 exome- sequenced sun-exposed melanomas having matched germline DNA. WT, wild type.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </floats-group>
  </article>
</pmc-articleset>
